IMGT®, the international ImMunoGeneTics information system® (http://www.imgt.org) provides a standardized way to compare immunoglobulin sequences and to delimit the FR-IMGT and CDR-IMGT in the process of humanization and engineering, whatever the chain type (heavy and light), whatever the species (e.g. murine and ) [1-3]. IMGT® is based on the IMGT-ONTOLOGY concepts Im of classification (IMGT and allele nomenclature approved by HGNC and WHO-IUIS), of description IMGT/HighV-QUEST, IMGT/DomainGapAlign and IMGT/mAb-DB: (IMGT labels), and of numerotation (IMGT unique numbering). IMGT/HighV-QUEST analyses NGS data (150.000 sequences per batch). IMGT/DomainGapAlign analyses amino acid sequences per domain, Muno provides the CDR-IMGT and FR-IMGT delimitation and the evaluation of the number of IMGT novel IMGT® contribution for antibody engineering and humanization physicochemical classes changes. IMGT/mAb-DB provides links to IMGT/3Dstructure-DB (if 3D structures are known) and to IMGT/2Dstructure-DB and IMGT Colliers de Perles (if sequences are Gene available in INN or in the literature). These new tools and database contribute to the invaluable help Véronique Giudicelli, Eltaf Alamyar, François Ehrenmann, Claire Poiron, Chantal Ginestoux, Patrice Duroux, Marie-Paule Lefranc Information brought by IMGT® for the analysis of recombinant antibody sequences and further characterization of system® specificity or potential immunogenicity. IMGT®, the international ImMunoGeneTics information system®, LIGM, Université Montpellier 2 Tics [1] Lefranc M.-P. Mol. Biotechnol. 40, 101-111 (2008) [2] Lefranc M.-P. et al. Nucleic Acids Res 37, D1006-1012 (2009) CNRS UPR1142, IGH, 141 rue de la Cardonille, 34396 MONTPELLIER cedex 05, France [3] Ehrenmann F. et al. Nucleic Acids Res 38, D301-307 (2010) [email protected] http://www.imgt.org The IMGT unique numbering and the IMGT/HighV-QUEST and IMGT/DomainGapAlign tools provide the delimitations of the FR-IMGT and CDR-IMGT for the analysis of antibody paratope or loop grafting in antibody engineering. The IMGT/mAb-DB with its links to the other IMGT® databases and tools, based on the IMGT-ONTOLOGY concepts, IMGT® is funded by the Centre National de la Recherche Scientifique (CNRS), the Ministère de l'Enseignement Supérieur et de la Recherche, bridge the gap between sequences and 3D structures facilitating the analysis of antibody/antigen interactions. IMGT founder and director: Marie-Paule Lefranc ([email protected]) Computer manager: Patrice Duroux ([email protected]) © 2010 F. Ehrenmann and C. Ginestoux Université Montpellier 2, Agence Nationale de la Recherche BIOSYS (ANR-06-BYOS-0005-01) and the European ImmunoGrid project (IST-2004-0280069) Bioinformatics manager: Véronique Giudicelli ([email protected]) Interface design: Chantal Ginestoux ([email protected]) © Copyright 1995-2010 IMGT®, the international ImMunoGeneTics information system®

Analysis of antibody sequences: IMGT/DomainGapAlign NEW IMGT/Collier-de-Perles IMGT/3Dstructure-DB contact analysis

IMGT/DomainGapAlign displays your sequences with IMGT gaps and, for ‘V’, with delimitations of the FR-IMGT and CDR-IMGT, according to the IMGT Antibody amino acid sequences are analysed per domain using the IMGT/DomainGapAlign tool. Several sequences of the same unique numbering for V-DOMAIN [3], and for ‘C’, with delimitation of the strands and loops, according to the IMGT unique numbering for C-DOMAIN [4]. CDR-IMGT lengths FR-IMGT and antibody humanization Make your own IMGT Collier de Perles CDR-IMGT lengths domain type (V or C) may be analysed simultaneously. If one 3D structure is available (for example 1ce1 for alemtuzumab), it is Clicking on the ‘IMGT Collier de Perles’ button gives access to the complete IMGT Collier de Perles with, for V-DOMAIN, the list of AA class changes, [8.10.12] possible to query IMGT/3Dstructure-DB [7,8]: [8.10.12] compared to the closest germline V and J and alleles. A standardized comparison of V domain sequences for antibody humanization Using the IMGT/Collier-de-Perles tool, IMGT Colliers IMGT/DomainGapAlign QUERY includes the delimitation of the FR-IMGT and CDR-IMGT, the determination of the de Perles can be displayed: • to visualize hydrogen bounds in the IMGT Collier de Perles on two layers CDR-IMGT lengths (e.g. [8.8.13]), the percentage of identity between FR-IMGT to check the table. The tables show that all hydrogen bond Paste your domain sequences in FASTA format. Select ‘V’ for sequences of the variable domains of the light and heavy chains. Gene and allele Species Domain Smith-Waterman Identity percentage Overlap • on one or two layers • contact analysis Select ‘C’ for sequences of the constant domains of the light and heavy chains. To delimit the domains (CH1, CH2, CH3) of the heavy IGHV4-59*01 Homo sapiens 1 494 73.0 100 [calculated on 91 amino acids for VH (FR1-, FR2-, FR3-, FR4-IMGT: 25, 17, 38, • with the VH or VL coloring of the CDR-IMGT interactions of alemtuzumab with its ligand (CD52 mimotope) only involve IGKV1-33*01 Homo sapiens 1 551 86.3 95 11) and 89 for V-KAPPA (FR1-, FR2-, FR3-, FR4-IMGT: 26, 17, 36, 10)] and the chains, an easy way is to check with IMGT Alignments of alleles (in IMGT Repertoire). Select the number of alignments to display. • with the IMGT amino acid physicochemical classes amino acids from the CDR-IMGT. number of IMGT amino acid physicochemical class changes. [6] for the FR-IMGT. This allows to evaluate the number of IMGT amino acid class changes. D-REGION N-REGION N-REGION L-INTRON-L V-REGION J-REGION

DONOR-SPLICE ACCEPTOR-SPLICE CDR3-IMGT DONOR- alemtuzumab_VH SPLICE IMGT CDR1- IGHV4-59*01 IMGT CDR2- FR1-IMGT FR2-IMGT FR3-IMGT FR4-IMGT 3'UTR (Homo sapiens) 5'UTR V-D-J-EXON INIT-CODON V-INTRON 1st-CYS CONSERVED-TRP 2nd-CYS J-TRP

alemtuzumab_VL L-PART1 L-PART2 V-D-J-REGION IGKV1-33*01 (Homo sapiens)

V-DOMAIN FR1-IMGT FR2-IMGT FR3-IMGT FR4-IMGT Total Gene and allele Species Domain Smith-Waterman Identity percentage Overlap IGHG1*01 or *02 Homo sapiens 1 634 100 98 VH (V-D-J-REGION) 25 17 38 11 91 IGHG1*01 or *02 or *03 Homo sapiens 2 742 100 110 IGHG1*01 or *02 Homo sapiens 3 738 100 107 VL (V-J-REGION) 26 17 36 10 89

CDR-IMGT lengths Humanized used in oncology [5] CDR-IMGT lengths [6.3.9] AA with IMGT [6.3.9] Humanized CDR-IMGT Closest Homo sapiens FR-IMGT class change alemtuzumab_CH1 antibody antibody gene and allele identity in FR-IMGT IGHG1*01 (Homo sapiens) 84.61% 14 alemtuzumab [8.10.12] IGHV4-59*01 (77/91) alemtuzumab_CH2 74.72% IGHG1*01 VH IMGT/DomainGapAlign RESULTS (Homo sapiens) bevacizumab [8.8.16] IGHV7-4-1*02 (68/91) 24 IMGT/DomainGapAlign identifies the closest germline V-REGION (for ‘V’) and the closest C-DOMAIN (for ‘C’). The IMGT gene and alemtuzumab_CH3 90.10% IGHG1*01 trastuzumab [8.8.13] IGHV3-66*01 (82/91) 9 allele name of the closest sequence(s) from the IMGT reference directory is (are) provided with a percentage of identity. (Homo sapiens) 97.75% For instance, the V-REGION of the alemtuzumab domains are identified as having 73 % and 86.32 % identity with the Homo sapiens alemtuzumab [6.3.9] IGKV1-33*01 2 Gene and allele Species Domain Smith-Waterman Identity percentage Overlap (87/89) IGHV4-59*01 and IGKV1-33*01, respectively. Homo sapiens IGKC*01 1 659 100.0 102 VL 92.13% The constant domain of the light chain has 100% identity with Homo sapiens IGKC*01. The combined results of CH1 and CH3 of the bevacizumab [6.3.9] IGKV1-33*01 (82/89) 7 heavy chain identifies the Homo sapiens IGHG1*01 (CH1: K120, CH3: D12, L14) (there is no amino acid difference with IGHG1*02). trastuzumab [6.3.9] 93.25% IGHG1*03 would have been characterized by CH1: R120, CH3: E12, M14. IGKV1-39*01 (83/89) 5 IMGT nomenclature is based on the CLASSIFICATION axiom and concepts of IMGT-ONTOLOGY [1]. IMGT gene and allele names alemtuzumab_CL Note that the use of the IMGT unique numbering would enable to reach 100% were approved by the HUGO Nomenclature Committee (HGNC) and by the WHO-IUIS Nomenclature Committee [2]. They are used IGKC*01 by Gene (NCBI), GeneCards, Vega (Wellcome Trust Sanger Institute), Ensembl (EBI)... (Homo sapiens) for the FR-IMGT identity. Positions to be checked for antibody humanization: 39 (FR2-IMGT) as it interacts with CDR3-IMGT and anchor positions 55 and 66. [1] Lefranc et al., In Silico Biology 5:45-60 (2005) [3] Lefranc et al., Dev. Comp. Immunol. 27:55-77 (2003) [7] Kaas et al. Nucl. Acids Res. 32: D208-210 (2004) [2] Lefranc. WHO-IUIS report. Dev. Comp. Immunol. 32:461-463 (2008) [4] Lefranc et al., Dev. Comp. Immunol. 29:185-203 (2005) [5] Magdelaine-Neuzelin et al. Crit. Rev. Oncol. Hematol. 64: 210-225 (2007) [6] Pommié et al. J. Mol. Recognit. 17: 17-32 (2004) [8] Ehrenmann et al. Nucl. Acids Res. 38: D301-D307 (2010)

IMGT/mAb-DB NEW IMGT/V-QUEST and IMGT/JunctionAnalysis IMGT/HighV-QUEST NEW

The nucleotide sequences are analysed with IMGT/V-QUEST and IMGT/JunctionAnalysis: • IMGT/V-QUEST identifies the sequences with the closest gene and allele in the IMGT reference directory, displays the 1 V-REGION most frequently occurring AA per position and per FR-IMGT and CDR-IMGT nucleotide and alignments according to the IMGT unique numbering and provides an extensive analysis of the The IMGT® database for therapeutic monoclonal antibodies Shows a set of tables, for each FR-IMGT and CDR-IMGT, indicating the most frequently occurring AA per position, its occurrence number and its mutations (analysis of sequences by batch of 50, synthesis view, advanced parameters) [12]. frequency. High-Throughput analysis of NGS rearranged nucleotide sequences of IG and TR IMGT/mAb-DB Query page • IMGT/JunctionAnalysis analyses accurately the junctions of antibody rearranged sequences (IGHD genes and alleles, N- and 1 P-REGION, “gc” content, amino acid physicochemical properties, pI) [13]. IMGT/mAb-DB is the monoclonal antibodies mAbs and FPIA approved for therapeutic and diagnostic use (in 2010) Analysis Submission Analysis Outputs 2 The IMGT/mAb-DB Query page allows requests on several IMGT/V-QUEST QUERY IMGT/HighV-QUEST has been developed by IMGT®, the international database of IMGT®, the international • Provide a title for the analysis. fields. These are organized in 5 sections: adalimumab panitumumab golimumab canakinumab ustekinumab Analysis title: (50 characters or less) • Select the species and the 5 Human (2002) (2006) (2009) (2009) (2009) ImMunoGeneTics Information System® [14], to answer the problematic of the Species: IMGT_HighV-QUEST_main_folder (named according to the analysis title) receptor type of the 2 Sequence number 1 : seq1 ImMunoGeneTics information system® mAbs HUMIRA® / VECTIBIX™ SIMPONI™ ILARIS® STELARA™ 3 Receptor type or locus: compared with the human IG set from the IMGT reference directory 1 TRUDEXA® sequences to analyse. T IMGT/mAb DB ID Sequences are from a single individual: Not indicated 1_Summary.txt analysis of the antigen receptor data from Next-Generation Sequencing (NGS). The • Upload the text file containing >seq1 (http://www.imgt.org) that is the global reference in Give the path access to a local file containing your sequences in FASTA format gaggtgcagctgttggagtctgggggaggcgtggtccagcctgggaggtccctgagactc 2 Browse... T tcctgtatagcctctggattcaccttcagtagctatcctatgacctgggtccgccaggct INN and other names muromonab-CD3 edrecolomab ibritumomab tiuxetan tositumomab capromab the FASTA sequences. 2_IMGT-gapped-nt-sequences.txt 5 Murine ccaggcaaggggctggagtgggtggcaagtatatcatatgacggaagttataaatataag 2 analysis of the expressed repertoires of antigen receptors - immunoglobulins (IG) or gtagactccatgaagggccgactcaccatctccagagacaattccaagaacacgctgtat 3 (1992) (1995) (2002) (2003) (1996) Results of IMGT/JunctionAnalysis T ttggaaatgaacagcctgacagctgaggacacggctgtgtattactgtgcgaggacagct immunogenetics and immunoinformatics. characteristics and structure mAbs ORTHOCLONE OKT3® PANOREX® ZEVALIN® BEXXAR® PROSTASCIN*T® 3_Nt-sequences.txt 4 Start The outputs are archived in ttctttaacgcctatgacttctggggccagggaaccctggtcaccgtctcctcagcctcc accaagggcccatcggtcttccccctggcaccctcctccaagagcacctctgggggcaca Shows the results of IMGT/JunctionAnalysis for the user sequences, per chain type. Amino acids of the JUNCTIONs are colored according to the IMGT AA physicochemical classes [5]. T 4 specificity (target name and target species) antibodies and T cell receptors (TR) - represents a crucial challenge for the study of Selection for results 4_IMGT-gapped-AA-sequences.txt gcggccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaac IMGT/mAb-DB provides a unique expertised abciximab rituximab basiliximab infliximab cetuximab tcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactc A. Detailed View Nb of nucleotides per line in alignments: 60 a single file in ZIP format tactccctcagcagcgtggtgaccgtgccctccagcagcttgggcacccagacctacatc 5 clinical indication, development status and clinical domain. 5 Chimeric (1994) (1997) (1998) (1998) (2004) Analysis of the JUNCTIONs T 5_AA-sequences.txt tgcaacgtgaatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatct mAbs REOPRO® MABTHERA® / SIMULECT® REMICADE® ERBITUX® the adaptive immune response in normal and disease-related situations. 1. Alignment for V-GENE 5. Se quence of the JUNC TION (nt and AA) 10. V -REGION mutation and AA change statistics tgtgacaaaactcacaca RITUXAN® Input V name 3'V-REGION N1 P D-REGION N2 P 5'J-REGION J name D name Vmut Dmut Jmut Ngc 2. Alignment for D-GENE 6. V -REGION alignment 11. V -REGION mutation hot spots resource on immunoglobulins (IG) or monoclonal 3. Alignment for J-GENE 7. V -REGION translation 12. Se quences of V-, V-J- or V-D-J- REGION T which comprises: Result summary: ; 8. V -REGION protein display (nt and AA) with gaps in FASTA 6_Junction.txt 5 user_seq_80 IGHV1-58*01 tgtgcggcaga ttctggat .tattactatggttcggggag...... agccct .....tactactactacggtatggacgtctgg IGHJ6*02 IGHD3-10*01 0 0 0 7/14 4. Results of IMGT/JunctionAnalysis Productive IGH rearranged sequence (no stop codon and in-frame junction); with full list of eligible D-GENEs 9. V -REGION mutation and AA change table 13. A nnotation by IMGT/Automat V-GENE and allele;IGHV3-30*04; score = 1255; identity = 93,06% (268/288 nt); IMGT/HighV-QUEST, the high-throughput version of IMGT/V-QUEST, can analyse without list of eligible D-GENEs user_seq_42 IGHV1-58*01 tgtgcggc... ggg ggaatatcaagaact.. gtatggccactatac ...... tatggacgtctgg IGHJ6*02 IGHD1-7*01 0 4 0 10/18 1 T J-GENE and allele;IGHJ4*02; score = 204; identity = 91,67% (44/48 nt); daclizumab palivizumab trastuzumab alemtuzumab omalizumab ranibizumab eculizumab natalizumab bevacizumab certolizumab pegol nimotuzumab Check all | No ne | D efault 7_V-REGION-mutation-and-AA-change-table.txt antibodies (mAb) with clinical indications, and on user_seq_33 IGHV1-58*01 tgtgcggca.. cccccat ....tagtgggagctactac gatcgg ...... ctactgg IGHJ4*02 IGHD1-26*01 0 0 0 9/13 D-GENE and allele by IMGT/JunctionAnalysis;IGHD5-5*01;D-REGION is in reading frame 1; 11 Humanized (1997) (1998) (1998) (2001) (2003) (2006) (2007) (2008) (2008) (2008) (2008) FR-IMGT lengths, CDR-IMGT lengths and AA JUNCTION;[25.17.38.11];[8.8.11];CARTAFFNAYDFW; user_seq_22 IGHV1-58*01 tgtgcggc... gg ggtacgattggaa.... ggtgt attactactactactactacatggacgtctgg IGHJ6*03 IGHD1-1*01 0 2 0 5/7 batches of 150,000 IG and TR rearranged sequences in one run. The tool provides B. Files in CSV Similar to IMGT/V-QUEST T 8_V-REGION-nt-mutation-statistics.txt 1 11 files in CSV format which mAbs ZENAPAX® SYNAGIS® HERCEPTIN® CAMPATH® / XOLAIR® LUCENTIS® SOLIRIS™ TYSABRI® AVASTIN® CIMZIA® THERACIM® Closest V-REGIONs (evaluated from the V-REGION first nucleotide to the 2nd-CYS codon) fusion for immune applications (FPIA). MABCAMPATH® 1. S ummary 7. V-REGION-mutation-table Score Identity 2. I MGT-gapped-nt-sequences 8. V-REGION-nt-mutation-statistics T L06615 IGHV3-30*04 1255 93,06% (268/288 nt) Translation of the JUNCTIONs 3. n t-sequences 9. V-REGION-AA-mutation-statistics 9_V-REGION-AA-change-statistics.txt recapitulate results for all M83134 IGHV3-30*01 1246 92,71% (267/288 nt) an easy to use and highly cutomizable interface which is already familiar to 4. I MGT-gapped-AA-sequences 10. V-REGION-mutation-hot-spots M77300 IGHV3-30*09 1246 92,71% (267/288 nt) es IMGT/mAb-DB is a relational database using the 5. A A-sequenc 11. Parameters T M77324 IGHV3-30*14 1246 92,71% (267/288 nt) etanercept alefacept abatacept rilonacept 6. Junc tion 10_V-REGION-mutation-hotspots.txt sequences of the run. X92283 IGHV3-30-3*01 1246 92,71% (267/288 nt) 4 FPIA (1998) (2003) (2005) (2008) Check all | No ne | D efault ENBREL® AMEVIVE® ORENCIA® ARCALYST™ IMGT/V-QUEST users. The standardized analysis is based on the T 11_Parameters.txt 1. Alignment for V-GENE open source MySQL (http://www.mysql.com) Advanced parameters <------FR1-IMGT ------seq1 gaggtgcagctgttggagtctggggga...ggcgtggtccagcctgggaggtccc L06615 IGHV3-30*04 c------g------...------Selection of IMGT reference directory set F+ORF+in-frame P With all alleles With allele *01 only IMGT-ONTOLOGY concepts [15,16] and the results are as detailed as in IMGT_HighV-QUEST_individual_files_folder 2 The 'Detailed view' for each M83134 IGHV3-30*01 c------g------...------management system database. Search for insertions and deletions Yes No M77300 IGHV3-30*09 c------g------...------M77324 IGHV3-30*14 c------g------...------Parameters for IMGT/JunctionAnalysis Nb of accepted D-GENE in IGH JUNCTION default Nb of accepted mutations: In November 2010, IMGT/mAb-DB contains 30 monoclonal antibodies and FPIA default in 3'V-REGION T X92283 IGHV3-30-3*01 c------g------...------IMGT/V-QUEST, including the identification of the variable, diversity and joining default in D-REGION Sequence 1 individual file analysed sequence that allows the Since 2008, amino acid sequences of mAb (suffix default in 5'J-REGION 3. Alignment for J-GENE on the market: 29 of them (25 mAb and 4 FPIA) are for therapeutic use and 1 Score Identity T Nb of nucleotides to exclude in 5' of the V-REGION for the Nb of nucleotides to add (or exclude) in 3' of the Sequence 2 individual file visualization of the individual X86355 IGHJ4*02 204 91,67% (44/48 nt) genes and alleles, the detailed analysis of the junctions, the analysis of the Parameters for "Detailed view" evaluation of the nb of mutations (in results 9 and 10) V-REGION for the evaluation of the alignment score (in results 1) J00256 IGHJ4*01 195 89,58% (43/48 nt) (shown with *) is for diagnostic use. 2 M25625 IGHJ4*03 177 85,42% (41/48 nt) -mab) and of FPIA (suffix -cept) from the World results. J00256 IGHJ5*01 174 82,35% (42/51 nt) mutations... The results are formatted in CSV and text in order to facilitate statistical X86355 IGHJ5*02 174 82,35% (42/51 nt) seq1 gacagctttctttaacgcctatgacttctggggccagggaaccctggtcaccgtc Health Organization (WHO)/International T Sequence n individual file X86355 IGHJ4*02 ...... --ta--t-----a------J00256 IGHJ4*01 ...... --ta--t-----a------a------processing. M25625 IGHJ4*03 ...... g-ta--t-----a------a--g------Analysis History J00256 IGHJ5*01 ...... ac---tgg-tc----c------a------Nonproprietary Name (INN) Programme have been Conjugated or radiolabelled mAbs in IMGT/mAb-DB X86355 IGHJ5*02 ...... ac---tgg-tc---cc------

entered in IMGT®. Users can follow the A query on a name allows to retrieve the International For each entry, IMGT/mAb-DB provides the origin species IMGT/mAb-DB also provides information on company, Monoclonal antibodies can be used: IMGT/HighV-QUEST is available from the IMGT® Home page (http://www.imgt.org). ‘Analysis history’ status of their The results are lists all analyses analyses (completed, compressed as a single 11_Parameters Nonproprietary Name (INN) and INN lists numbers as (human, rat, murine, humanized or chimeric), the isotype and clinical indication (more than 200 in the database), launched by a user. ZIP file to be downloaded. conjugated with another molecule running..). Date: Tue Jul 27 16:07:44 CEST 2010 provided by the World Health Organization (WHO)/INN format, links to IMGT/2Dstructure-DB (amino acid developement status, organization that approved the drug 1 IMGT/V-QUEST programme version: 3.2.15 IMGT/V-QUEST reference sequence release: 201027-3 Programme, the Common name from literature, the sequences and IMGT Colliers de Perles), links to such as Food and Drugs Administration (FDA) or European Title User Global Result Submission Date N° of sequences Species Receptor type Actions Species: Homo sapiens IMGT/mAb-DB: Relations with other IMGT® databases Calicheamicin, a cytotoxic antitumor antibiotic Human IG Eltaf ALAMYAR completed 2010-08-19 11:29:26 CET 108721 Homo_sapiens IG Download ( 441.47 MB , 108731 Files ) Remove IMGT/V-QUEST reference directory set: F+ORF+in-frame P Proprietary name if the antibody or fusion protein for IMGT/3Dstructure-DB (3D structures), specificity (target), Medicines Agency (EMA), application (diagnostic or Mus musculus TR Eltaf ALAMYAR completed 2010-08-24 18:50:57 CET 150000 Mus_musculus TR Download ( 588.06 MB , 150010 Files Remove Search for insertions and deletions: yes 2010-08-26 13:39:07 CET Ex: gentuzumab ozogamicin , MYLOTARG ® Synthesis view results H. ig with ins/del Eltaf ALAMYAR running 108721 Homo_sapiens IGH Not completed Cancel Nb of nucleotides to add (or exclude) in 3' of the V-REGION for the evaluation of the alignment score: 0 predicted completion time: 2010-08-27 at 20:22:08 CET immune application (FPIA) is a registered trademark origin clone species and origin clone name. therapeutic) and clinical domain. Nb of nucleotides to exclude in 5' of the V-REGION for the evaluation of the nb of mutations: 0 2010-08-26 13:39:34 CET Scientists believe Alexander the Great was killed by calicheamicin, a dangerous compound produced by a IMGT/HighV-QUEST, the high-throughput version of IMGT/V-QUEST can be used for: M. TR with ins/del Eltaf ALAMYAR running 150000 Mus_musculus TRA Not completed Cancel predicted completion time: 2010-08-29 at 14:11:31 CET Number of sequences 50 Note: this table is not dynamic, please clickh ere to Refresh the table 10_V-REGION-mutation-hotspots Genetic approach (symbol®). bacteria (Micromonospora echinospora) found in water. (Squires N. , Telegraph, 03 August 2010) 1. Result summary Sequence number Sequence ID Functionality V-GENE and allele (a/t)a t(a/t) (a/g)g(c/t)(a/t) (a/t)(a/g)c(c/t) Genomic approach 31 L26531 productive IGHV5-51*01 aa,37-38(FR1)|aa,39-40(FR1)|aata,5,689-5-790(F(FRR11)|)t|att,,6795a--77g06c(t(F,F8RR-111))|(|ttFaa,R,88122)--|88a33g((cCCaDD,a2RgR41c-12)t),|7t|8ta(t-,F181R180(1-9F8)-R|19g1(gC0)t|tD(a,C7gR3Dc1-cR7),|164ta)(1|,Fa-14Ra04,191()-F4|1aR21g-10c1)(t4|C,a83Dg5(Fc-R8tR,182)(5|)Ct|-at8Da,81,R1(6C6199)D-|1-aR17g710c0)(t|,C(a1CgD0Dc6RtR-,2112)00)|9t|6at(a-,C1,10D9992R2(-C1-1)9D|9g3R3g((C1cC)tD,D|1tRgR1c282c)-),|1|t1ta2a3,1,141(9-F9199R3--2720()0F|0a0R(g(FF2cRa)|,3t32a))5c||ta3ct,a,-212,1295126-5-(21F-129R2153(6(F)C(|FRaDRg3Rc)3|a2t)a|,)a2|,a27g6,42c2-42c-427,2-6720(342F(5-FR2(R3F0)3R5|)(3|Ft)aR|t,a3,0)2|4a6-g23c-02c56,2(3F3(RF7-R32)34|t)0t|,a(3Fa0R,623-83)3|0t-a27c8(Fc4,R(2F36R)2|3-2)|6ta5,(3F0R43-3)|0a5g(cFcR,237)|7ta-2,38007(F-3R038)(|FtaRc3t,)3|07-310(FR3)| Structural approach • the analysis of repertoire of IG antibody sites and TR recognition sites in normal and pathological 32 L21957 productive IGHV6-1*01 ta,5-6(FR1)|aa,40-41(FR1)|aa,10ta3,-51-064(F(CRD1)R|t1t,)1|a1a4,-11g11g85ta-(1,C31D-96R((FF1RR)|2t1t),)|1a|a4ag9,c1-1t6,5820-a1(gF16c(3RtF,(28FR)-R1|ta)21|,)a(1|Ftg6aRc9,a1-,61)1|97a4-0g-11(c7C7c0D(,(4FCR1RD-214)R)4|t|2a(F)g,|1Rtca7a1,2,1)1-|7t10g270c-3-1c1(7,C06339D((-CRC7D2D(R)RF|t2aR1),)|1a|g)9a|gt0,gc1-ca18t,94,111-210(8C8-5-D11(3CR111D2(()FRC|tRa2D2,)1R|)t|a91g,2)g1|-ac91ta09,1c-315t(,9C511-1D1(8C5R-81D2(2)RF|1tR2t(,)F12|tR9)a|8g2,1-g)19|tta92a,9-c11(t8,F9183R6-(139C9)-D|11ta7R(C,22(D0)C|6RtDa-2,2R1)0|92a79)g(|-aFt2aaR0,c203c0(),4F|2t-aR22,8320-)272|t7(a3F-,12R2(203F86)R|(-aF23gR0)t|7ta3,2(a)F|5ctRt7c,2,-325)36|9a50-a2-(,2F623R018(43(F-)F2|RaR1g353c)()|ttF|,a2R,a633c90c)-4|2,a2-7a352,032(5F-22(5RF5-3R62)(23|Fg6)Rg|(tFtc3,t3R),2|03a96)g7|-tc3a-t30,207620(79F(F-R2R3273)82|)(|FR3)|aa,c2t3,257-42-3267(F7(RF3R)|3a)a|t,a2c5t0,3-20571-3(F10R(3F)R|a3a),|253-254(FR3)|aa,274-275(FR3)|ta,304-305(FR3)|ta,307-308(FR3)|aa,315-316(CDR3)| IMGT/LIGM-DB 33 X94075 productive IGHV5-a*03 aa,2-3(FR1)|aa,37-38(FR1)|aa,3t9a-,6409(-F70R(1F)R|ta1,)6|t9t,-7750a-(7gF6cRt(,F18R)-|1t1a1),(|8tFa2R,-88123)-|(8aC3gD(cCRaD,1a2)gR4|tc-1a2t),71|8t(t0-,F189R1-81(1-F18)R|09g(1gC)t|Dta,7Rg3c1-c)7,|a64taa(1,F,-114R04192()-F-|1a1R1g4103c)(t(|C,Fa8DRg5c-R28t),18|t)a(5|Ct,-t18,D178R64(7C-11-)D17|a6R5g8(1cC()tC|,Da1DRg0Rc62t-2),1|1)t0a|0ta9,61(,-19C1070D-491R-(91C117)D(|5aCR(gCD1cDR)t,|R1a21g)2|8ct)a|t-t,1,t1,219182(9--F1-R12991230()(F|C(aCRgDDc2Rt)R,|22t2g)3|)ca7|cta-a,2,1,141390946(2-F-1-11R3993773)((|F(aCRgDc23aR))||,t2ta)5c,|1t3ca9-,,129195-92690(--F1029R(0F530R()(C|F3aDR)g|aRc3a)2|,t)2t|,a172a541c-12t,-17126791(62F-(R1F93R9)3|(a)Fa|tRa,23,24)46|a-2g2-c42c56,(32F(0RF2R3-2)3|0t)a|5t,a(2F,63R203-42)-|63a30g(5cFt(R,F23R3)73|a-)2a|t4t,2,038(03F6-R-23380)4|7t(gF(FcRcR3,32)|)5t|a8,-320641-(3F0R53(F)|Rta3c)c|t,a2,6320-72-6350(8F(FRR3)3|a)|gcc,277-280(FR3)|tact,307-310(FR3)| Sequences The submission time in CET When a user removes or cancels an nucleotide/ Link to IMGT/2Dstructure-DB From IMGT-ONTOLOGY to INN definition Exotoxin A from Pseudomonas aeruginosa The Synthesis view allows to have an overview of the V genes and alleles identified in a 9_V-REGION-AA-change-statistics34 Z80499 productive IGHV3-23*01, or IGHVt3a-,2338*-0349(FR1)|ta,109-110(CDR1t)t,|1aa3,-142(F-1R413)(|tFt,R324)-a|3tga5c,(1tF,68R5-1-1)1|6t(aF6,R(3F81R-)3|2g9-gC(cFDtR,3Ra11g2)-|c)3t|tt4,a8(,2F-11-R681813(-F)(1|CRg6Dg19t)(Ra|Ca,13Dg)6|cRt-tc3,2,849)8|1(t-Fa-84,R9141(7(C)4F|aD-R1gR17c)15a|)a(,|C1gta0Dc,3c1R-,0712920)-|-6t17a(1C5,10(DF8(CR9D-11)R)9||a10g)(|CctattD,,,11R1068265-)--1|t1a206,1916((9(FCF6RDR-21R2)9-|1g7C)g(|DFtcgRtc,132c3),1|2t1at-,1,13-6915791(-F-412R(60C820D()(C|FRgDRg1cR3)|t)a2,|1ag)4|act6at,,2-,1111744849--2-(1F127R515(2(F()FC|RaRD3g2R)c)|ta|2,a1a)g|6,tc2a2t4,-,11486-29254--(1F596(RF052R(()CF|3gRD)g|2Rata)a2|,t,1)a2|7tc5a2t0,-1-12975651-(1(CF9DR97(R3F)2R|a)|3ag),g|2atta5ag,3,c1-c928,9572-4-721(70F9-0R2(83FC0)RD|(tFa3RR,)2|t36)t,|)2g|a-g22gt6t6c,-23c22(,22F478R-(25F32-R)27|a83(aF8)|,(Rt2Ft,362R)94|3-62)|-7t2a04c(7tF,(3RF03R7)3-|a3)a|1ta,02,(27F64R-223-7)2|56(3F(FRR3)3|t)a|t,a3,0320-23-0330(3F(RF3R)3|t)a|t,a3,0340-43-0350(5F(RF3R)|3ta)|,t3t,0370-63-0380(7F(RF3R)3|a)|a,316-317(CDR3)| Genes situations, analysis, or fifteen days after the Sequence number Sequence ID Functionality V-GENE and allele V-REGION Nb of positions including IMGT gaps (AA) V-REGION Nb of AA V-REGION Nb of identical AA V-REGION Nb of AA changes V-REGION +++ V-REGION ++- V-REGION +-+ 3D Structures (Central European Time) is 35 AF013615 unknown IGHV6-1*01 ta,5-6(FR1)|aa,40-41(FR1)|aa,10ta3,-51-064(F(CRD1)R|t1t,)1|a1a4,-11g11g85ta-(1,C31D-96R((FF1RR)|2t1t),)|1a|a4ag9,c1-1t6,5820-a1(gF16c(3RtF,(28FR)-R1|ta)21|,)a(1|Ftg6aRc9,a1-,61)1|97a4-0g-11(c7C7c0D(,(4FCR1RD-214)R)4|t|2a(F)g,|1Rtca7a1,2,1)1-|7t10g270c-3-1c1(7,C06339D((-CRC7D2D(R)RF|t2aR1),)|1a|g)9a|gt0,gc1-ca18t,94,111-210(8C8-5-D11(3CR111D2(()FRC|tRa2D2,)1R|)t|a91g,2)g1|-ac91ta09,1c-315t(,9C511-1D1(8C5R-81D2(2)RF|1tR2t(,)F12|tR9)a|8g2,1-g)19|tta92a,9-c11(t8,F9183R6-(139C9)-D|11ta7R(C,22(D0)C|6RtDa-2,2R1)0|92a79)g(|-aFt2aaR0,c203c0(),4F|2t-aR22,8320-)272|t7(a3F-,12R2(203F86)R|(-aF23gR0)t|7ta3,2(a)F|5ctRt7c,2,-325)36|9a50-a2-(,2F623R018(43(F-)F2|RaR1g353c)()|ttF|,a2R,a633c90c)-4|2,a2-7a352,032(5F-22(5RF5-3R62)(23|Fg6)Rg|(tFtc3,t3R),2|03a96)g7|-tc3a-t30,207620(79F(F-R2R3273)82|)(|FR3)|aa,c2t3,257-42-3267(F7(RF3R)|3a)a|t,a2c5t0,3-20571-3(F10R(3F)R|a3a),|253-254(FR3)|aa,274-275(FR3)|ta,304-305(FR3)|ta,307-308(FR3)|aa,315-316(CDR3)| amino acid sequence Ex: oportuzumab monatox, PROXINIUM™ VICINIUM™ query, with the number of sequences (between parentheses) for each V gene and allele. For 31 L2635631AF01361p6roductivperoductIiGveHV5-51I*G0H1 V4-31*03, 1o0r 5I G(1H0V6a)4a-3,410*-0441(FR1)|ta,109-110(CDR1tt),4|ta5,-14162(F-1R113)(|Ctt,D190R78a1 (-g)91|c8a0t)a,98,(1-C14D12(R-F114R)3|1t(a)F|,gR1g12c2)t|-,t81a21,g1-3c86(t5C,38(-DC-11R6D141R((F)F1|RtR)t,|11g2)g5)||at8ttag,-1,c105c66,949-(1-F10-R479240()C(8|FCt2DaRD,R11R516)2| )3t(|)a1a-|tc16gat)6c,14t,07(1F921R-812-171)32|2t(a1C,(1DF6R921-1))||7ataa0gg,(c1cCa9t,D,611R-1318219-)-711|t(2t3F,14R(7(F31R)-|1t2a7)),|2|1tga(9gCc9tt0Da-,12,R19062601)-(|1-Ft1a9R6,9134(9)F(|F6aR-Ra13,292))|70a|a(2aFg-c2Rcca0,32,3)10|(t9F2a0R-,1-23190)995|a3-((a2FC,0R42D013(R4)F|-2tRa2)c31|ac)5g|,(t2ttFt,2,2R28223-752)-|-3t22a122,(288F2((RF8R3-2)3|2a))9||ata(acFg,c2Rt,a323,352)|-3t2a7-32,-224534(6F30(F-R(2FR3R)34|3)t(a|F)a|,Ra2gg3ct9)t,|,2-t22a654,9270-3-2(29F76-R20(34(FF)0R|(taF33,R)2)||a34g)9|ct-a2tt,,5220764(49F--2R2753720)|((tFt,R2539))||-ata2gga6cc,c02t,(52F378R-4523-52)|478ta(78F,(3FR0R34)3-|3a))||0ata5,2c(6Ft,83R-03276)-|9t3t(,13F00R(6F3-R)3|t03a7),|3(F0R4-33)0|5(FR3)|ta,307-308(FR3)| Monoclonal Antibodies indicated for each analysis date of completion, all sequences 32 L21957 productive IGHV6-1*01 106 101 98 3 0 1 2 Antibodies represent a large number of the pharmaceutical substances submitted 37 AF013619 productive IGHV4-39*01 aa,40-41(FR1)|ta,102-103(CDR1tt),4|ta5,-14065(F-1R016)(|CtaD,1R0a12g)-|1ctat0,,231-(05C9(DF-1R110)(||CtaagD,1cR0t,158)-a|1tag01,c6(1Ft(,1C2R2-D1-51)R(|1Fg13Rg)(c|1Cttt),,D|81aR20g-81c8-t)51,|8a(0C-a91,D(1CR4(FD21R-R)1|1a14)g)3||att(agF,,cR1c012,042)|-1-t1a1-04,113436((C5F-RD1R16)611|t()a)F||actRtgt,,21t1t-5,0C1890D--161R5-112920)((|F9tCa(RDC,12RD6)|R91ta-)11|,a1)7|g6g0c5g(cC-c1,t1D,613R61(28-F1)-R|13ta24,1-(1CF(7FRD2R2R-12)2|7)t|)a3g|tc(gaCtc,1Dt,961R6942-61)-|97t1a904,(19FC7(RFD4R3-R1)22|7a))|5a|t(ctgC,c1taD,72,R106-213)-7|2-t12a06(,51C6(9FD(F6RR-R13229))|-7|aCta(FD,c1RRc7,324))5-||t1a3a7g-,125c95(aC96,1-D(2F9R0R0-231())F9||ta3Rg,(31Cc)9tD|,a62Ra-61,2929)-0|72a2(7gF-2t2Rt(,02F335R)(|7Ft3a-R)2,|1a639g0)|9c(aF-ta,2R2,0273014)(|4-aF2-gR27c173t5,()2F|(tF6aR9R,32-32)3|)7t3|at2-ac2(,tF32,3R4303(7F-)-2|Ra333g14)c0(|t(F,aF2R,R72343)-9)|2t|a-72,724(30F9(RF-23R4)3|0g)(|gFttc,Rt2,325)9|a7-2a-36,2050(F0(F-R2R353)1|)t(|aF,R3034)|-a3a0,525(F3R-235)4|tt(,F3R036)-|3a0a7,2(F6R8-32)6|9(FR3)|ta,304-305(FR3)|ta,307-308(FR3)| example, 4 user sequences express IGHV1-58*01. Clicking on the gene and allele name • the identification and characterization of new alleles, plus the completion time and results are fully deleted from 8_V-REGION-nt-mutation-statistics33 X9430875M67502productivperoductIiGveHV5-a*I0G3HV1-46*01, or IGHVa1a-4,367*-0328 o(Fr RIG1H)|aVa1,-4406-*4013(FR1)|aatt,5682-5693((FR11))|0|at6aa,,8720a--8g73c1t((,CF8DR-1R11)1(|Ft)a|Rt,t8,182)8-|g8-98g389c(Ct(,C2DaD4gR-cR21t17),8|)(ta|F-t1,aR11,01(F9)0|R-9g1-g11t)t01|,a6(0Cg0(CcD-6cDR,34R1(1F)1|-Rt)4a|1t4,a1)(9,|F1g10R2g1-c211a-)11|,a371g(23Cc-(7tDC,51RD(0F1R6R)-1|1t1)a0|)t,|9a1a(,1g1C4c1D-t4,11R-1101516)(|5-Ca1(aD0Cc9RDc(1C,R18)D1|6a)9Ra|t-,t11,1)74|4g239g(-C1-c1t4D,514R04(F(26FR)-R|1a0242g)9|)ca|(taFa,1,R,1196262)4-|1-g-119g669ta35(F,((1FFR80RR372)2-)|1)a|t|9gtaa0c,1,(t1C,627D464-R9-11-62275)75|(a2F(0gC(RcFDt2R,R1)3|9a2)6a|)a|-,t1ga69c,1c98,-(21F97R-7103-9(2)C0|8a(D0gCR(tDtF,22R)0|23t9a)-,|1t2a71c,421t,-(931F907R-7523-(0)3C|0g1D(g0FRc(RFa2R3,)2|)t32|at)t0,|,12-2812913--1(2F910R2(3(CF)D|RaRg3c)2|a)ta|,a2,a25,6312-92-525-613(9F(6FR(RC3)3D|a)R|gta2c,)t3,|2t0a64,19-39-2907-52((0FF0RR(3F3)R)||ta3t,g)3|ca0a6,,-23700487--(2F70R79(3(F)|R33))||ta,262-263(FR3)|ta,304-305(FR3)|ta,307-308(FR3)| to the World Health Organization/International Nonproprietary Names Sequence number Se3q4uZe8n0c4e9 9ID Funcptriodnuaclittivye V-GEIGNHEV a3n-2d3 a*l0le1,l eor IGVH-RVE3G-2I3O*N04 Nb of positions including IMGT gaps (nt) V-1R0E6GION Nb of nucleoti9d8es V-REGION Nb of identica8l 0nucleotides V-REGION Nb of8 mutations V-R1EGION Nb of si1lent mutations 1 IMGT/ Monomethyl auristatin E (MMAE), a synthetic antineoplastic agent provides the alignment of user sequences derived from that gene and allele. evaluation for all running the system to respect data 31 L23655A31F013615 producntkivneown IGHVIG5-H5V16*0-11*01 316 (320) 29120 (6296) 101 266 (267) 99 26 (29) 2 5 (61) 1 0 (WHO/INN) Programme [9]. The INN definition of antibodies is based on the Ex: glembatumumab vedotin • the qualitative and quantitative analysis of mutations analyses. confidentiality. 32 L23169A57F013616 produpcrotidvuective IGHVIG6-H1V*041-31*03, or IG31H9V 4(3-3210*)04 30140 (6305) 99 81 300 4 (5) 18 1 (21) 2 4 2Dstructure-DB 33 X93470A7F5013619 produpcrotidvuective IGHVIG5-HaV*043-39*01 318 106 99294 88 280 11 14 1 1 53 INN sequences 7_V-REGION-mutation-and-AA-change-table38 M67502 productive IGHV1-46*01, or IGHV1-46*02 or IGHV1-46*03 106 98 80 17 1 0 7 IMGT-ONTOLOGY concepts of classification (nomenclature), description (labels) Several displays are available: Sequence number S3e4qZu8e0n4c9e9 ID Funpcrotdiouncativliety V-IGGEHNVE3 -a2n3*d0 1a,l loerl eIGHV3-R-2E3G*0I4ON FR1-IMGT CDR1-3IM20GT FR2-IMGT 296 CDR2-IMGT FR32-I8M4GT CDR3-IMGT 12 3 • the evaluation of the frequency of the variable (V), diversity (D) and joining (J) genes and alleles 31 L3256A53F1013615 proudnukcntiovwen IGIHGVH5V-65-11**0011 c7>a,Q3>K(+ - -)|c10>g,L4>cV7>(+a ,-Q +3)|>aK5(8+> -c ,-K)|2c01t>08>H2g>(-,g L-,4 Y3+>2)V|80g(>6+D0 ->( -+c -), K|-a)25|a0c88>1>5H4c>7,(K-g> 2,-gS 0+|2>)9|Ha>7(D-0 -(> -+c -,) K|-g)2|6g4308>0>6Q5c>,(aK+,a2 S-10 2-7>)9|0Hg>>7(Dg-3 (,->-Y +a-5 ),-7G|a)>|27gW501>0(I-c7( ,->+K -c -2 ,-)S4)|t|>3g1Q67>41(+T> t(g-,+G ,-Y )-2|5 g+577g>)>|31Ic(W>91- a073-( ,8->0-G )>1c+|2t,t 8R,-5S)2>6|3>I66(g>->, YT-T 2-(()-+8| g-> -7-D )+4|g(>)c-|3 2t-1, 0G-074)29|>a>5>c8t>c|,5gRI,(>Y2-1g2 30-,57 S6->)>2|cL9T,(Q>4-( -D-7 -(-5 -)-> |)a-|H a1-)3(1|-g10 +88>6 >t-,>)cY|aa,3R,2S712>209L96>(>->tD ,-T (-(-7)- |7- ->- )-S|)g|(c1+30 1-7 9>+>c)|,acS|233164>>Tt(|t+2 5- 1+>)|c,1I0884>tT,S(-3 -6 >-)T|c(2+5 -5 +>)t|t|g10296>7c>,tY|a3279>5L>(-t ,-T -9)|9a>1S10(+> t-, Y+3)|7>L(- - -)|c147>g|a170>g,Y57>W(- + -)|t171>g,Y57>W(- + -)|g197>c,R66>T(- - -)|c204>t|g225>c,Q75>H(- + -)|a229>t,T77>S(+ - +)|c234>t|t251>c,I84>T(- - -)|c255>t|g267>t|a295>t,T99>S(+ - +)| genes/ and numerotation (IMGT unique numbering). It provides the closest V and J Bouganin, from Bougainvillea spectabilis Willd toxin 32 L3261A95F7013616 propdruocdtuivcetive IGIHGVH6V-41-*3011*03, or IGHVa3411-03861 >(*30g24,S0)36>G(+ + -)|c110>t,A37>V(+ - +)|a12a41>0g6,I>42g>,SV3(6+2> 9-G7 + (()+2|g 9+29a 9)-1)|2>c41a>1| g0,>I4t,2A>3V7(>+V -( ++ )-| +)| g2912>73a|24 (26) a320>g| 3 (5) amino acid sequence 3D Structures/ • Alignment for V-GENE 33 X3974A0F70513619 propdruocdtuivcetive IGIHGVH5V-4a-*3093*01 a3>g|c45>t|g74>c,G25>A(- a+3 >-)g|g|c8465>>t,tS|g2794>>I(c-, G-g -28)5|6g>>1At1,(S93- >2+a90 -,>S)I|(4-0 -> -N)|(-g -1 -1)|9c>1a94,S>4a0,T>6N5(>- N- -(-)2 |+9 9-)|gc210934>>aa,S,T6685>>NN(-( -- +-) |-t)2|40>c|c255>ag,2S08325>8>4aR,S(-6 -8 ->)|Na2(-5 -6 >-)g|t,2T4806>>cA|c(-2 -5 -5)|>t2a15,S58>85c,>TR8(6-> -A -()-| a- 2-5)|c62>6g4,T>8t|a62>8A3(-> g- ,-K)|9t255>8E4>(+c, T- -8)6|g>2A9(1-> -a -|)|c264>t|a283>g,K95>E(+ - -)|g291>a| genes and alleles corresponding to the amino acid sequences with, for the Ex: citatuzumab bogatox expressed in the input sequences, 6_Junction 34 Z3880M49697502 propdruocdtuivcetive IGIHGVH3V-12-34*60*10,1 o, ro IrG IGHHVVc3381-21-7439>6* t(0*|3g0421201 o)9r >IGa,HSV410->4N6*(-0 3- -)|c164>t,A55>V(+ - +)c|a8177>5t|>g,S5299>5G (2(+9 6+g) 1-)1|g91>8a7,S>4t,0G>6N3(>-Y -( -+) |-c 1-)6|g41a>81t,87A>55a>5,gG>,VS6(35+>9 Y>- G(++)( |+- -+)| t-1)9|g61>8a7,Y>t6,G6>6N3t1(>-9Y -6 (2->+)6a| t7-2, Y-2)6|8g6> 1(>c28N,9F8)(7>- 6a-> ,-GL)|(6ta+233 2>-1 6Y-7)>(>|a+cg2, F-,5K 7-0)16>|0>c6L,K>(+R8 4(-+> -8 Q)+ |(a( 9+2) )5-| 0-)>|gc2,K6814>>aQ|c2(+7 9- >-t)||ag321671>>ga,|Kc120769>Rt|(+ + +)| genes/ nucleotide sequences IMGT/ Sequence number Sequence ID Functionality V-GENE and allele J-GENE and allele D-GENE and allele JUNCTION frame JUNCTION JUNCTION (with frameshift) 3'V-REGION P3'V N-REGION N1-REGION P5'D D-REGION P3'D P5'D1 proteins Analysis Management 35 AF013615 unknown IGHV6-1*01 a215>g,K72>R(+ + +)|g273>t|a274>g,N92>D(+ + -)|c276>t,N92>D(+ + -)| a215>g,K72>R(+ + +)|g273>t|a274>g,N92>D(+ + -)|c276>t,N92>D(+ + -)| 31 L26531 productive IGHV5-51*01 IGHJ4*02 IGHD3-22*01 in-frame tgtgcgaccaacagtggttattaccccggggatggctttgattactgg tgtgcga ccaac agtggttattac humanized (-zumab INN suffix) and human (–umab INN suffix) antibodies, the 36 AF013616 productive IGHV4-31*03, or IGHVa42-3>1g*,0Q41>R(+ - -)|a8>c,Q3>aP2(>- g- ,-Q)|1t4>5R>(c+|g -8 -3)|>aa8g,>G8c32,>Q8a>3,D>GP(2-( 8- >-)D -|a)(|-8t 48- 5>->)t|a,caI13|82084>>>Ft,c(I+3,I 04- >2-F>)|aL(+1(+ 1- 3+-)> |+at,)1Y|a131383>4tFt,1>Y(6-t3, 9H+8> >4-g)5F|,a>(Y-1L 52+(7-4 ->->) D|c-),(|I-t4 1-26 ->3)L|>a(c1+,9 Y+05 >+5g)>|,aHS16(3+44 >->t 1G-t,9)H(|6+4> 5+g> ,-YL)|(6-6 -> -D)|t(1- 6-3 ->)|cg,23Y215695>>ctH|,aV(3+72 6-0 >->)L|ct(1|+6 9- >+g)|,aY25374>>Dg(,-I 7- 8-)>|aM1(9+0 +> g-,)S|t26345>>Ga(+,S +7 9-)>|tT1(9+6 >- g+,)Y|a6263>7D>(g- ,-S -7)|9g>2T26(+> c- ,+V)7|g62>3L8(+> a- ,+V)8|a02>3I4(+> g- ,+I7)8|a>2M40(+> t+,V -)8|t02>3I5(+> a- ,+S)7|g92>4T6(+> c- |+a)2|a5273>7t,>Qg8,S6>79L>(-T -( +-) |-a +2)7|g42>3g8,S>9a2,V>8A0(>- I+(+ - )-| g+2)|7a52>4c0,>St,9V28>0A>(I-( ++ -- +)|g)|g228406>>cc,V|a9245>7L>(t+,Q - 8+6)>|t3L0(-6 -> -c)||a274>g,S92>A(- + -)|g275>c,S92>A(- + -)|g280>c,V94>L(+ - +)|t306>c| • V-REGION alignment according to the IMGT unique numbering 32 L21957 productive IGHV6-1*01 IGHJ3*01, or IGHJ3*02 IGHD3-16*02 in-frame tgtgcaagaggccgttggaccgcttttgatttctgg tgtgcaagag gc cgttggacc • the analysis (lengths, sequences) of the third complementarity determining region or CDR3-IMGT 37 AF013619 productive IGHV4-39*01 c13>a,Q5>K(+ - -)|g31>a,Gc1113>>Ra(,-Q -5 ->)|Kc4(+3 >- g-,)P|gc138517>>>Aaa(,-|Gc -91 -31)|>t7tR|4(>- c- ,V-)2|ca541>32A>4(g>+,g P-, 1I+45)2|>c>A8V(7-(> +-a -|) c|+t97)3|4>>t|ca,1Va221456>>6gA>,(Ig4+,2I 5-> 6+V>)(|V+ (-+ + -) |+a)1|a6167>5g>,I5g6,S>5V9(c+>2 G-4 (+9+)> |a+g1 |-a7)2|5a6>19g9>,3Sg>5,Kg9,9>T0G6>5(R+> (A++ ( --+) |- a +-1)9|c32>7g1,T>6t|g5>27A5(-> -a -,)S|c9224>9N>(g-| a- 2-)6|9a>3g0,5K>9t0,Y>1R0(2+> +F +(-) |+c 2-7)|1>t|g275>a,S92>N(- - -)|a305>t,Y102>F(- + -)| mAb-DB 33 X94075 productive IGHV5-a*03 IGHJ4*02 IGHD2-8*01 in-frame tgtgcgagacatgggactactagtgcctggtcaagatttgactactggtgtgcgaga c atgggactactagtg 3D Structures percentage of identity of the V regions [10]. Amino acid changes of the constant radiolabelled with an isotope gene name(number of sequences) IMGT/HighV-QUEST manages analyses in three layers: 38 M67502 productive IGHV1-46*01, or IGHVg11-436>*c0,2V 5o>r LIG(+H -V +1)-|4a63*80>3g,Kg1133>>Rc(,+V +5 >+L)|(g+6 -0 +>)a|a|ag38681>>gca,|,KaV18231>>RtI,(Y(++2 -8+ +> +)F|)ag(|g1-7 613+05> ->c)|,ataA,|M8g25635>1>9t>>P,TaF(-,2(V +-9 2 >--1) S|->a)(I8|+(g1+ 1-> -1+c 7+|)ta|>)1c|8tg81,3M790>3>43t>,c9Yc|t>2,,TAF832>(+55F> >(--I P( -+-)( |- -t- 1 -)- |3)-a|)8g8|>15c0>|7ta,>T1c24,94S>3Sg6|(>a+gT1 -1(6 +93 7)>-| c>g+1c,)I0,|5S456>>6t,V>T(T3+5( +-> +I-( )-+| -g) |-3g)1|2g501>20t>7|at>,3Ac1,6S683>>6gS>,R(T- (1+0 -6) >+|aG)2|a(21-9 1-> 5-g)>|,taT,M372730>9>>AtF|(-( +- -) -|a)|2g51167>>gt,,TM8369>>AF((-+ - -- )-|)c|t216318>>gc|ca217414>tg|a|a219603>>tg,E,I9575>V(+- +- +-))||gt128991>>ca|g,E1997>Vc,(S- 6+6 ->)|Tg(3+0 -1 +>)a|g,V210021>>t,AI(+68 -> +S)(|g- 3+0 -3)|>aa2,2V91>0g1,T>7I(7+> -A +(-) |- -)|a256>g,T86>A(- - -)|c261>g|c271>t|a290>t,E97>V(- + -)|g291>a,E97>V(- + -)|g301>a,V101>I(+ - +)|g303>a,V101>I(+ - +)|g315>t|a316>g,R106>G(- - -)| 5_AA-sequences34 Z80499 productive IGHV3-23*01, or IGHV3IG-2H3*J034*02 IGHD3-3*01 in-frame tgtgcgagagagccttctgggggcggttcttttgatatctgg tgtgcgagaga gcc ttctgggggcggtt Sequence number Sequence ID Functionality V-GENE and allele J-GENE and allele D-GENE and allele V-D-J-REGIONV-J-REGION V-REGION FR1-IMGT CDR1-IMGT FR2-IMGT CDR2-IMGT FR3-IMGT CDR3-IMGT JUNCTION J-REGION FR4-IMGT IMGT/GENE-DB genes/ • V-REGION translation (which corresponds to the most diverse loop of IG and TR amino acid chains in contact with the 1 The web service layer manages interactions with users (analysis 35 AF013615 No results region, by comparison with the reference alleles (and expected allotypes [11]), 31 L26531 productive IGHV5-51*01 IGHJ4*02 IGHD3-22*01 EVKVVQSGAEVKKPGESLHEISVCKQVVISQGSDGDAFEETVVTKKLKWVPVIGQWESSGVLARHEQGISVMDCKDPKQFGPITSKGTGELDLSWEDLWFHITIGMSTWCGLQWIVIWIRISGQPWGMDVPRSGDQIKWTMGTPPLYGEGSDWKPSGMSDLFGTEQIWGTMHYVGSSIPIIWSFAPQDGGKDSHSTVDASSTTITNSAYSAYSGDLPQYKSYSWFPTQSGSSGTDCLHAGKAYVAFTLSDSNQISDYWASGDSAYKMSYSLPYKTYGFASCDSTAGYDATWFYSNDLAGSQYMQGWYGYYSYTCSPLWLGIIKVDGASGQSFGDDTSYLAWIMIVGYSYQSCGATLIIVSS IMGT/ 36 AF013616 productive IGHV4-31*03, or IGHV4IG-3H1*J034*02 IGHD3-3*01 in-frame tgtgcgagatcccctcattggcggggttattatgcgaaagtacatgatgtgcttgttctggaatgaatctgg tcccctca ttggcggggttattat 3D Structures submission and history, results download..). 32 L21957 productive IGHV6-1*01 IGHJ3*01, or IGHJ3*02 IGHD3-16*02 QVQLQQSGPGLVKPSQTLSQLVTQCLAQISQGSDGSPVQGSVLSVQNKLGPQVSQAQSWTGNLPSWGLDVLTVRSCKVQAPSISSPGQNSDTGRSLGVVSAWLSLETSNWCNWALGVGIVSRRAQTWSYNPYWSRTRSYVGKYRWRLQESYSWKNPWLSDGRYRNAGVDLSEYVWAKVLSGRVRIKTSIYNRYPIRATDSIRTNKGSPWKRDNWYTQNSTDFKASNYFLAQDQVCFLSANVRLSKQGVSLRTRNWPISTETVIDNATTPFADEFVTFDDYSWTYFKACWNVAQYGRYFQGSCGRLTQWMLTGVNATQSFVGDSTTFSPMWEVGDTTQVAGSVTSYMYVCTAVRSS Indium-111: Half-Life 2.80 days, used in nuclear medicine to observe tumors and 37 AF013619 productive IGHV4-39*01 IGHJ4*02 IGHD6-13*01 in-frame tgtgcgagacatggcagttttgccagcacctggtctttatattttgactcttggtgcgagaca tg gcagttttgc cagcacctggt and those of the FR4-IMGT, by comparison with the closest germline J genes and antigen). 33 X94075 productive IGHV5-a*03 IGHJ4*02 IGHD2-8*01 EVQLVQSGAEVKKPGESLREISVCQKLAVSQGSYGIAFTEESVVYKQWKLPVINGQWESSVGLRARQEGISVMYCKPIFKGTPAKSGSGYGEWLSYEILWFRTIMINSGWYCRWKVIARDINSQPWSMVDPRSGQYIKDNMGPNPLSYGEDNWKSPGYMSLNFGEQRWGNMHYGVNRTPIISDAFPDQSKDGSSHIYRVANATRNIAHSYGANLDTQPTKSWSFASIQRWSAGLCSAHEARYAVRFLSTQHDIDSGYWTATASDTMSKSLYSAEYIWRFACDASAAYDRYWTFHLADGQMYTEWWYTGYSSCSALLWVEISGVARSEFSDGDTSYALWMVIYGVYESCGSASRLVIVSS 3Dstructure-DB • V-REGION protein display 38 M67502 productive IGHV1-46*01, or IGHV1IG-4H6*J042*0 o2r IGHV1-46*03 IGHD3-10*01 in-frame tgtgctggagttcagggggtggcccggcctttaggggactgg tgtgctggag ttcagggggt LCD manufacturing, 2 All tasks concerning the launching of the analysis and the 4_IMGT-gapped-AA-sequences34 Z80499 productive IGHV3-23*01, or IGHV3I-G23H*J034*02 IGHD3-3*01 LVQPGGSLRLSCAASGFTFLSVSQYAPMGGNWSLVRRLLQSVACQPAPGAGSKGGSFLLETRFWLGSSVSFCSYTVAAFIASMSSGNYGWAGVYRSMQTNANWPYGVAKRDGQSLVAEKPWGISRVKGSLGTVGLIIEGSWRYGDSGVTNSGSVYQSNNTYTNALYDYASLDVQSKMVGNKRSGLALRTRILSEATRPEISSDRGTNDAGSNVQGSYNSQYCTFCNLDAATYIRRLEYQEPLPMSQSNGMGSGGNLGSGRFSLASDRFEFIDADWEIITWWGDATGVAYVYYCYWCGAR alleles, are indicated based on the IMGT numbering per domain. This information Sequence number Se3q5uAenFc0e1 3ID615Functuinoknnaoliwtyn V-GEINGEH aVn6d-1 a*0ll1ele J-GENE and allele D-GENE and allele V-D-J-REGION V-J-REGIONQVQVL-QRQEGSGIOPNQGVLVQFKRLPQ1S-QIQMSTGLTPSGLDLTCVSCDKVARPSIS1S-GIQNMDTSGSLATVSAWSLTSNFCNRWAS2II-RASIMAQWGSTPNSWTRYIGRCYLQDRESRSWP2K-SLWIMGRYGRNLTDEYWFARLVG3S-RIVMTRGYSYTRRIATSRIKNCWPDDYRNT3S-DIMKYNAGQVTSFVSJRLUQSNRLCDITSIONVPTNPDETJDS-RKTEANGVQYIFOYSNCLQLFDRS4V-ITMPGETDTAVYYCAR preparation of the results are performed by background routines. 31 L26531 productive IGHV5-51*01 IGHJ4*02 IGHD3-22*01 EVKVVQSGA.EVKKPGESLHISCQISGEDVDKFV..V..QTTSLGWAE.IEGVVWKKVVKVRPQQGSMEGSPAGL.HEDKVIDGSKFCLK.EQ.P.W.ITGSTMGELGSDWLIDIIGHWFIW.SP..CGV.TQR.T.DQILSSWMDPIGTGTWIKWYGVSPRLPGEQS.WF.MDQMPS.GDKTHI GVTLSYEISWPAMSDFKGQSII.TWGSHPTAGVATS.Y.NDILSSQAGDWDYTKSTYSSYPTLSGSKPDCTASGASFYFDTQLDNS.QGYSAWGMHVYSSYSIPCLSFGKAADATDYSNGKWDSSFGSDTAYSQMYTWGPAYTGYWLLCDIIQGVGWSQFSDGSYTSWLIKIGVAQSSGDTSLAIMIVYSYSCA 36 AF013616 productive IGHV4-31*03, or IGHV4I-G31H*J034*02 IGHD3-3*01 RVPLQESGPGLVKPSQTLSRLTVCPTLVQSEGSDGSPFGRSLVSVPGKLGPQSYEQFSWTGLSPSWGGLLTLDVCRSKTQFPVSLSPSQGGTDKGLSGYSFLFWLSETSWCGWTIGVLHYRSIFQDWLYPSGWGIDKGLYGRTSLDQGEYLWGNPTGPIGSKHLGKLDSEYRWNLITPGMSHLTIKDIDSYTRSSLGAKTGRNMTSLTDFPISDYHLNTWKSPLRKSAGNLSKYLLCSFYTASRAARLKAKTSVDLMPHTAHTDASIWAVDLFYTRDYASGCIDAKYADNYRFTLAFDASKSPVIVWLHYHKYGWDLCQARGSFGLDWRYTIMYWGAAVAQKTDGVTRHSAMDSVAVYFTYDVCISAWSRGQGRMVTVSS is obtained with the IMGT/DomainGapAlign tool (http://www.imgt.org). Ex: capromab, PROSTASCINT® • V-REGION protein display (with color) 32 L21957 productive IGHV6-1*01 IGHJ3*01, or IGHJ3*02 IGHD3-16*02 QVQLQQSGP.GLVKPSQTLSLTCAISGQDVSQVLSQ..QSSNGPVQ.AGVWQLVLNKQWPQVSSRQGQTGPLS.DSGPSLLTVRCSKGA.P.LSISENQWGGTDLVLWSGSAVRNLSTW.YC.SVYANRRISGQSVS.KAPWWSTRYNNGYWDRLVEYSRWA.KQVLWSGVYPRKNSD.RSYGRALIVTESIWNVPLKDG.STRRSTAIKTYRNIYNGQRPRFSDSW.KTLTWSQAKLYFNNDQSDCFVFYATSARPLVGQESRDLVNWTKAS.TSVARYTFAIYPTDFCEIDFNDAWFPRTWDAGTGVRSYQWKYGNTCWTAQMFFGDVSQFTLGWVQTSLGMSNQVSGTVTVMSPSEVDTVTSASVYYCAR Sequence analysis happens on the resources layer. 37 AF013619 productive IGHV4-39*01 IGHJ4*02 IGHD6-13*01 QLQLKESGPRLVKASETLSLQTLCQTLAKSEGSGGSPIRSQSLLVSQKSLAYKSYEEWSTGLPWSRLGVTLGRCVQSKTIPASPSSGESTKGSLGYSSYLISLWETSWCGSITSWGAYSVSYVRWYQYGPGWPGVVSYKRAYGQYGLPYEGPNWSGPAIKSGGLSKLYESYWRNVIGPTSISLVVKYDSYTRGSVGKATSNRISAQHVYFGDYSSNTLFSPRAKSLSNLTKQSWCSVFARSTSRLVALYTHARFIDGLSDNTSVSASFDVATFTSYATKFCAWNDADQSSRTWFLAHSYGVFLFQRSDYGFLSCNATWSPWTVWTGAVSQASLGDSYTTFPADVVSTFWVYGSCSQARGTPVTVSS 3 33 X94075 productive IGHV5-a*03 IGHJ4*02 IGHD2-8*01 EVQLVQSGA.EVKKPGESLRISCKASGEYVIQF.L..V.TQSSYGWAEI.NEVWVQKVLKVRPQGSMEGPSAGL.REKYVIGISFKLC..KE.K.PWTAGSSMYEGGWSYRLIINRIFD.WI.SP..CVSTR.KS.DAYQSWMYPINGNWIKDYVGNPRLSPQE.S.WMDFSQPMYG.GNKRHGVNLTYEISNWAPMDSGKFRQSI.RDGAPHASVRY.T.DLHISQGAYWTDNTSKNSSSYALINWREPACSSAARFDYRFQLTHDQ.AGGYMWHTYSVTYTSCILASAFEWADRADSYHSKRWGDSFTGIDRATEYSMAGWAYSWYYLWLCSVQGRIVWEFSDSGSSYSLWLEVGAIVESSGDSSTALVMIVYYSCSAR 38 M67502 productive IGHV1-46*01, or IGHV1I-G46H*J042* o0r2 IGHV1-46*03 IGHD3-10*01 QVQLLQSGAEVRKPGASVKQISVCQKLPLSQGSFGSAFEQIVTVYRQYKLFPLHGQWASSGVVRAKQEGIVSAFRCPSKGFPIQTGSGYGAYLSFEVSWKFFMITSHGYCWVYKVIFPNRHSPQWSAGVPRGGQTIQNTAPGYPSLSGGEQQWGKGTFMLQEGGWVRTMVYGASVMQITKNRFPQDSTGSGRTVTASATGAYMVVSTQYQRGMKDVEFTALQSSRGTSPSRLCLARVGAVSADGYVMVMDTQETRGALDVSITYASSYRLTCRWPSASLAGVGVQVDYQGTWMGASEILVYLVAYSTRCSVPLWSLRSGSDQVWDGTSGALQIVYGTYSVCLSAVSGTVSS This work was granted access to the HPC resources of CINES under the allocation 2010-03602 made 3_Nt-sequences34 Z80499 productive IGHV3-23*01, or IGHV3I-G23H*J034*02 IGHD3-3*01 ...... LVQPGGSLRLSCAASGFTF....S..S...Y..A..M..LNVWQVPRG..QG...AS..PL..RG..LLKVSGQCLPAEGAWSGFVGTSSFLV.RT.I.FSL.S.SG.S.C.GYSA.AS.AGMYSYANSMWTNNVWRYAVQDRASQPVGAIKSPK.GGGKLREG.L.GWTLEIYSVWSRSTVDSNVSYIQASNDGTSGLV..YKGL.YGQSRMTALNNRTSYIESLAPRDSADSGENVGDSKGTQ.GASNRVCFTYDLALTYIRYICELSAQPRRSMDEGNPGSSQGLFGRNSDGATFIGWEDLDYSIGWLFTQDAVMIWYNGYSWCLGRAEDTAVYYCAR • V-REGION protein display (mutations displayed) Sequence number S3e5quAeFn0c1e36 I1D5 Funucntkiononwanlity V-GIGEHNVE6 -a1n*0d1 allele J-GENE and allele D-GENE and allele V-D-J-REGION V-J-REGION QVQVL-QRQESGGIOPQN.GVQLVLKQPFQSRSQ1G-TGPILM.DSGGSLLTVCSKA.P.SISNQGSCTDADLWSASRVNL1SWT-.CI.SMIRANGQISTSAPASWTFRYNRGYW2LR-EIISRMW.QKGLSWGTPRYSNRDCGYDLAREVW2S-VILMRGG.RSTRYAITYFRIRNRSP3.-DKIMTWSGYKTNNDQYFACSVDLSQRVL3RD-I.SMVRGTITPINEJDPUDTNATVSCYKTYNIOCQNFSL3Q'VLD-RSEVGTPIOENDTAVYYCAR In November 2010, IMGT/mAb-DB contains 343 entries (175 -mab, 15 -cept), Iodine-131: Half-Life 8 days, used in nuclear medicine to observe a thyroid gland Web Service Background Routines Computational Resources 31 L26531 productive IGHV5-51*01 IGHJ4*02 IGHD3-22*01 gaggtgaaggtggtgcagtctggagcagaggtgaaagaaagggctcgcagagggggtgagtgcgtcacatgggcttcagtcgaagatagcgtcctgcatggtatgcgcagagatgaggttactatacgatggaagacgagtctgctaacgcagcagagtgccggttgctgtatacgacttgaccgatcgcattgcgctcccagtcctgccgagctgtgacggttcgcagcactgtgtggccttctgcgttcacggtgaggatccgtctatcatcgtatgatcagatcgctaatgcgcgcatccattgtcggtgccgtcaacgcgcggtatgtgttcatgtcccaactatagagcaggtgcgcgcatggcgactatgtgcgtgggatttagtcacgctgtctgtgcgaagaccatcctgttcagccaggcgtgagctgcgcagtgtgcaacagtcggtatactgagtacgatgtgtatgtcgccccactactgctccagcgtcgaggggagatcgaatacatcggggagcgtccacttctattgcgcgaacacttagcatacaggtcggtaggtggtacggcggcgatacgtccttacctcgatgaggcggccctcgcagtcctgggatcacttcctctcgacatgttcacacagctacgctagtattaaccacataggtttccccgatccccattgctcaacacggccctaacccgttcatcgctagtgttacgacgacgccgcatgcaagtgccccatcgcaggatcatccgccatatgctcattctaacgtgtgtgcagaccacgacacctgaagatggggtctactttcagcgcacctgcgcgggcactagtgctatttttgaactttgatcgtcgggaggccagggaaccctgatcattgtctcctca 1 (User Triggered) 2 (Scheduled) 3 (IGH,CINES) 36 AF013616 productive IGHV4-31*03, or IGHV4I-G31H*J034*02 IGHD3-3*01 RVPLQESGP.GLVKPSQTLSLTCTVSGRDVSPFLSQ.E.SSGGGPYR.GFVLWPVLSKQWPESLSQRGQTPGLL.SGPDLGLSTVKFCKGSTP.L.VSESQGWGTGIDLGYWSHFFLSITDSWC.Y.LSTRGV..Q.SGGLYGPFTGWIDDKSYYGNWSLP.EL.S.RWGLQGIKGL.TSPHRGLDKTYGMNLTPEISWDLTIKGS.HKSNIRDLAYFTRSSMS.L.T.PKGIHLDGAWTTSSRDLKGYTNNAYLCAPYFADSASRLTKLKSAVK.PVHLSHYADRYSWALCLTFRTAMDGDARTIAYSIDYFPTDAHSKAIWKVRNGHYGLYDQFCYAGSWYFRLADGKMKILWQVAGHTSVDRLSATMSAFVDATDIVWTSGASVQYGYRCMAVRTVSS and radiotherapy on cancers such as lymphoma, by GENCI (Grand Equipement National de Calcul Intensif). 32 L32719A5F7013619 prodpurocdtiuvcetive IGHIGVH6V-14*-3091*01 IGIGHHJJ34**012, or IGHJ3*02IGIGHHDD36-1-163**0021 cQaLgQgLtaKcEaSgGctPg.cRaLgVcKaAgStcEaTgLgStcLcTaCgTgAacStGgQgGLtSgQaIcSLaaK.g.gSEcgSctacSGtcYcPaYgQ.gRcWLcaLtQGgVLacKWKcaAcVgEcSccRaSEtagcGQTgtgcPLttGca.PSRacGcGLgtLaTcSKgVgaCItGSKccTt.cALg.AtSEacgSgSWEatGgSgTIcgaGcYLcgcaSWYatggLItVgScGtgTcYat.tWcCa.gYcScgTaGVSggAaggRS.t.gtScg.YQGcgtYcPaSacWtgPcAtgcaGtVYtagYKgWcgtYNgGctagVtGaPgLacgRaESt.ctc.cgQct.LWtGgcaKPgcSIga.GPgtScgAcgGtSaRcttctacKaVgYacGgTcYctgcgtcILtNagScgEtPaVcgaWcSagDtctcgtLITcatGaKcgScStct.cKtagScgVcgNcRcgaYcgtQaVtcAYatcactFTgRtGcgcSIaaHSt.ag.ctLcg.tVGacGgRatagcDSgtLSgatgtTFgNgAcgSAgacSYgtKSgctgVaYgtgNTttTNctagcWQaACPtaccgAFASgtcttSgDtatLRccgtLtKTaYgHcgRaA.cFatGcScgLcVDattcRSgaNaFSVtgFSaYcgATcgVCacISatTSAcFagTAVgRDgcaWAaDgtHSgttaDgTSgGWttgTSctaLgSgaGcAYaKtcFtctcgVFQNtaAcgcDFaQGgaSatYSgtcgFTtgcCatWtSWgPtagtaLtgVagSGaRcTcaLctQLcVgtYttNgcGgStFcatgStSgTDtggaVcPSatagaTcVcWgaaAaTgcgAGcVacgaDagQSccgtTacSaGtAcgatTtaVtctcPgaFtcaVagYcctTacCtataVacgAcSttgcRgcStgagcagcgattacgtcgtcgccgctttgatgctaaagttcgtagtcatatagtcgtcgcaatgattgagatcactcgtcatcgtcagcataaacgaatgccgatacacgtagaacagtcgtcgtaggtttcaaatttaaacccttggcaattgtaatcgaccaagttcactactaggtgaaaccaagtttccgtcacacttagaccacgacttcgaaaaccctctaggtgaaccatccactccgcaaaaggaacaacccgaggcttcgttcgctactttgaccatgtcgtcgaaaagcatcgtgctgcagctttgcgccagccagacgtattctgaactgttgcctgtgtgggtactctacatgggtgcaacagaatgggtcaccgtctcttcc 213 have an INN and, among them, 81 have sequences in Other results include: 33 X39840M7657502 prodpurocdtiuvcetive IGHIGVH5V-a1*-4063*01, or IGHV1IGI-G4H6H*JJ0442** o02r IGHV1-46*03 IGIGHHDD23-8-1*0*101 gQaVgQgLtgLcQaSgGctAg.gEtVgcRaKgPtcGcAgSgVagKcISaCgaKgPgStgGQaFVaSQagFaLa.La.g.Qg.IgTcStcgYGtcYgAaFgQ.ggHEVcgVWtQagRVgLKLtRcgPQgQtcGcaSaAtgAGgPgSatAGctgVg.cQgEFKcgaVSaGIgStgRFcaLCc.tgKE.ctK.cPgWc.IPagtTGgMgStYAgtaGaYgcSgaFaVggFgSgaItKgHNgFtcIaaWPS.ct.at.SCg.caVaI.gKtTt.RagcGaYPagQtgGtYSgatAcaF.ctTaPccHgTcGtWgaYIaQNgtStVccgPGQtRagtSLtagKaQ.Eca.cFgGAtWatcQgtgPcGaagM.gtGagc.gTaGtcQRgtgtgVGaVccTcgAcaLgtYgtEtMgcgtaSgWcgTtQacgRMtgtKgcDaGaFcTttgQaVagStcI.gctNTGtcatgScgPaRgtgAaSgVgcVaG.tA.gtcaGYgcVMactcgtMtGQtgactTaaEc.taGRtTgccagLVgTDatSagcaYAgTcSctcSaRcatLcgtQcPTRgctaCSLaKcgStGcaAFtcgVcgtVQDGcctggtgY.tVagTcGtaMcgAQtgRtcaEIcGaYVtatLgcagVYAaSgagcCAgMSgttggRAaWgLTccgGPRaccgtGLgaVStDatgGQcgVcTgaDtGtDSgattcWSTcgVcagtALStgcaaVIARgcYcgTVaPtYagVWtYLCcgcSMGtagcGcStgDtEagQggtLWggcGaScgtGgcSacgacQLcagVaRtGatgcgTtScgSaaVVtatLattSgDtVgcSctTctacgAVtccacaIStgYcatSgtcYcggaCagagcAtactGacgtgcatacggtcaactatcttgctgagatacgcttgatagccgatgaggattgcgcgacgatccagcgttcacctcttgagagtgacgccgtaccgactctgcgatcgataccctctaaacttaccgatccacagactcgcttagacattacaacactgcgtctcgctacctcttacgcaagacgcggccccatactgcttcgaccacgatgtcgtacaggcaccggcactcgagaaggtgccactcagacgacccggccctaattcgttgacttaagcttggtgacggcaaggacccatgtgggaggagcctcatcctagatgccacctcggctccaaatgtaatttttagcatcgttagcctgaggagcgagggaagcctggtcatcgtctcctca analysis by standalone 2_IMGT-gapped-nt-sequences34 Z80499 productive IGHV3-23*01, or IGHV3-I2G3H*0J43*02 IGHD3-3*01 ttggtacagcctggggggtccctgagactctcctgtgcattggcgctatcctaggacctttcgagcgttgttttgaggttcaacccgatcgtcacgtgtagccgctgacgtgcggcagtatgcttcgtgcacgtacggtgatttcgtcaatgcctcgaatgctgaccggttatgcatttaggccctgtcatgtgtgagctgcgcctaccaagtgtgctcacgtgatgtgggcgccttgctgcaggctatgagagtggagatgctgatgagcttaatgcaggtcgtagcggcggattccagtcgtatagcgtacgtccgcgtgtacttggcgagatatgcggtagcgggatgtcagacatctagttgcggtcgtggcaggtcccggatagacggaccacaggttagctagctgctgcctgctgcatattctgtgtgtcacaatgacgtagtccgtgctaagatggtttgatccagcatggcgtagtgcgtggtatcgtacttgcgagtctatgtatcctatgacgtgccaaattccctatgcaccaacagtaatcgggaacaacgaaatgtctctctcgcaagggtagaagcacagccggggaccgtcaggtaagctcattcggacgcacaacagttcgttaactacaacttagagactgtcgattgcagaattgcccgaaggagaaccaaccggcgtactcagtctatgtactatacattggtagaccgagtacgtgaaggcactgtctcgggagggggaccgagcttgcgttcttcggattaattactttgagcgtggtcgcgagaga Ex: tositumomab, BEXXAR® FASTA Sequence number Sequence ID Functionality V-GENE and allele J-GENE and allele D-GENE and allele V-D-J-REGION V-J-REGION V-REGION FR1-IMGT CDR1-IMGT FR2-IMGT CDR2-IMGT FR3-IMGT CDR3-IMGT JUNCTION J-REGION Syntax control version of IMGT/V-QUEST 35 AF013615 unknown IGHV6-1*01 caggtacagctgcagccaagggttcaacgaggtcctcgacgagggacgcatgggtgcatagcgagagtgtcgctcactgctgcttaggcgctagagagactcgctgacagcaatgcgtctcccatagcgctcgcttacgtacacagccgtcatagcctcagccgccacgttcatcctgtcgcaatactcgtacatagctgatgggcggcagtctgagtttctagataccgtcgttgatcgttagcgaatccggttcgaagagacgatcaggcagagttagactcgccattgcagaacctgctgatggcaaatcaaggcaaggtccaacgataccgcacaactccaggatgtcatgcgccctgttcgaaggctgttgcattgtcgtggatgaagcgtaccactgaacgtagcaacgagctgcgccataggtgtgtagtttaatcatagttgattatgcagtatctgtgagaagtcgaataaccatcaacccagacacatccaagaaccagttctccctgcagcttgattctgtgactcccgaggacacggctgtgtattactgtgcaagaga Selection of analyses from 31 L26531 productive IGHV5-51*01 IGHJ4*02 IGHD3-22*01 gaggtgaaggtggtgcagtctggagca...gaggtgagagatagaagacgcgctgggggtggcagagagtgctgctctgtgagcaagcgcaatgt.c.gt.cgtgcacgtggaggtgacttgacagtgacgattatcgactctgtatgc..c.a...c.gg.g.aa.ga.cg.gt.gc.ga.tgaagcgcgtatctat.ca.gat.cc.ga.tt.cgag.t.tgc.g.cat.cg.ccaggcacagtctcgcatgtcggctagcattgctgctccttcgcagtgcgagtatg.tgtc.ct.ggt.ac.ag.ctgagcaatgtgcaggtcgcgagatctggctgatgccgtgacagcacgactgcttgactac.tcg.gt.ta.gat.ct.acg.tc.ctc.ag.ac.ag.aca.gcg.c.gagcagattaccgcattgcgattcggagtcgttgtcgactacctgctcccgagactgtgatcgcttgaaggcgatctagtgtcttgggagtcatgtgactgacttactagttagcgagatcgctactgcatcgatcgcgcgccacggtagtgatggcatagc.a.acg.a.tc.tg.ctggctaagtcgctctcaatcgtttctcgctagattgtagtcgtcgataccgtcgactgctaagagcgcaacgttctgcaactagcgtcggcgctctcctctgaggagt.a....c.g.t.gc.gcagccatccagtgtgcatcatacttcactctattcgatgtacccaggatccacaggtctcccttaccccaaag..t.agcgccgccacctagctccttctcagttttgcgaaggccaggaccataggatacgcagcctacggtgaacctgccccgtcaccacttgtctatgtatgcgtgatggccaggacctagaacaagggtcgcgttctagtgtaaccctccgcgcgagtagttgagttcatctttggatgttcagcatggggccagggaaccctgatcattgtctcctca IMGT/2Dstructure-DB and 14 have 3D structures in IMGT/3Dstructure-DB. By 1 the local queue to be Resource 1 36 AF013616 productive IGHV4-31*03, or IGHV4-I3G1H*0J43*02 IGHD3-3*01 cgggtgccgctgcaggagtcgggcccaggactggtgcagagggctcgcctcgacatggcaacgcggcagtgggttctcgcgccgctgcacctgcctagagcggaggacgacttgtggtacgctgtcgtgctagcagcttgtccgcaacagccgcttcgtcagcaggtctacgtagaggggctagttcgcgacagtgtcacattgtgcccgtctctcagctcgtcctgctaaacgctcatctactgtctcagtcagccgcaataccgggttggcggttgtcacgacctgcactctatggtcacggacacgtcagcccactcgtgactcgacatcgtcgtccgtgcagtcactgctgacaaagttatgtgcggtgcagacggactgctacgcatgattcatgctctgctatgtgccggatcaggaggattgagtcagtgctcactgtgtctaggattcgtctggagtccatcgtcgcgaagagcgcacaaccagtactgcgtgtacagtcacttatgcatcacgtaataaggctttggcctgcgtagttttagtcggatacgactcgaccttatccgctgagaaagtcgatacgtctggagcatcatccttctttgcagtcttgactcgctcactctgcatgatcagcgagatcgtagtccggaagcctagttcgaggcgcgcagctcgaatcgcctgagacatttcagtcatcgatcacctccctagatcgcacatcactaggttacgtctcgcatgcattaagccctagtggcacctgcatcttgactagcccctgcctagaggaacaacccgtgcttcgtctgcctatgctaaacgtgcttgcggcacgtcatctctgccacttcgactctgggccggggagcgatctagtgtactcggctgataacatgatcatgcatgtgcagtaggcattttgatatctggggccaagggagaatggtcaccgtctcctcag • V-REGION most frequently occurring AA 32 L21957 productive IGHV6-1*01 IGHJ3*01, or IGHJ3*02IGHD3-16*02 caggtacagctgcagcagtcaggtcca...ggactgcgatgggatagccacgccttcggccaaggcaacgctgctatacgctcgaatgccccttcaga.c.c.agcggtgcatagcggtcgtgcgaatctgcaagtgcatctggcgctagc.gtc.c.gtgtc.ag..cta.gca.ca.ggatgagtggagctctcagcttagcacgta.cg.g.tgt.cc.cta.cgactgttcgaacgctacatgatgtgcgattcgtacgccctccctaagatgcttcgctctgtgcaggccagag.tta.cagt.agcgtgactggcgacgtctgcagtatgtgcgttacatcgtgtcgatgcgtcatgctgatctatcgatg.tacg.gt.ca.g.ca.ggac.gag.c.caccagtgcagtgtcctagtggagtatggctcatgctaagcaccgcttttagttgtaggcgaactatagctctcggctcgtcttggtatggtggtgacaaacctcagtatgccgtagtatgctgtgcatcagtacaactctgctctcaatacgtcagcggcgaggtacatctgca..gta.cactcagcctgtgtgcacgagatctgagctcgatgcatctatgtacgatcgttcacctaggtcgaagctatctcatcggttaagcaaaggag.ct.c.aacg.g.t.cgagcaatgattgtagtatactttcaaacattctggataatctactcgacgaagctatccatgtctcgaagaa..a.acgctacggtatcattcacacctgccaatcgacatgcacaccatgcatgctagcaacttccccacaggaaagcacagctgtcgtcctcgctgtgtactatagccttgtagaccatacgtgatggacctcgcttcgggaaacgcagccattcttggacttttgctgtgagttgaccctgataggcgagaagcaagatggtcaccgtctcttcc Local Web dispatched based on 37 AF013619 productive IGHV4-39*01 IGHJ4*02 IGHD6-13*01 cagctgcagctgaaggagtcgggcccaagactggtgcaaaggcgtcgtctcaggcatggaaacgcgacatgggcttccgcgccgatcgacctgcatagaacggaggacgacttgtggctgcgccgttgcgctagaacaggctcgcagcagctattctgacggagggcatgattgcggcataatgcggtcagtctagatgtccagttcgacggctctattcccgtctcgtatagatgtcacaccgttcatgagccgccttcgcagcgacgtgtggtgtacccggcctatgccacagttcgcgagctacgtgcggctcgctcgctacagtacggactaccgctgccttgacagcatgccattatcgtgaatgtgaggtgcatcgagaatgtgggtttttgatctcgtagtccacatcgcgatgagatagagcgctgactagtcgccgtcgtatgtcatgtgatggcgatgtccctgattacttagtgcgagagccttcactgccattatgctgtagacaatctgcaactcgatcgtcagctggtagcgggtgttataacagtgcaccgttcgtcttgcgtcaatcgctgtcatattctggaatgagacgccatcttgtgtgctgcgacactgcctagactcgctagagctttacgtggaagcgtagtcgaggcgaccgatcgtagtgtcctctctttgaatccattgagactcaaccgctccggtacacgctacaacacgaaggtttctgcacgctgcacgcgatttgaatcaccgtctatggtagcaaccgtcccggacaaggaaaccaccagggtctctgtctgctctttgaacgtgttgtgcagacgtacctgattggagcccaggcttcttggccacgaagcacgcgtgcgtgtcttgttatttatctttggtagctgcattgagcgagccagggaaccccggtcaccgtctcctcag availability of computational 33 X94075 productive IGHV5-a*03 IGHJ4*02 IGHD2-8*01 gaggtgcagctggtgcagtccggagca...gaggtgagagatagacgacgccttgggggtgcagagagtgctcgtccttggcgaaagggccatagtc.g.t.ctgcacgtgagtgattagcagaccgaagcattcattcgattcgg..acg..ca..ttg.a.g.aac.g.at.cgatcatgtacgtatact.ca.tg.gta.c.ga.t.aga..catg.gt.gcg.cagcgcatcagctcgtatatgcggacaattcagtggcttactcagcatgcgtagg..tgca.c.gtga.t.acgaatacgcatctggcagtatgcgctgtacttactggtcacagtctagagccaccatgtcgtgt.agc.t.gc..gat.t.atcg.g.tca.gc.ac.cgacgc.tg.gc.ggaagggacgacatcctgattacgctcgcgtctgagccagatgtcgcagcaccacaagttctgtgtgcgtagtgctagatctgaacgcgctgcgatggaacgctcttacatagagaagtggcatcttgctatgcgccctaggctagcgtacgcgtgagagagagagta.caa.gc.at.gc.tg.tcgtcacgtcagttttcagctgctatgatatgcctgaggtagtctggtaacgatcagctgctacagcagagaacgcgctagctgtgatcagctgcttccctcatacgatg..a.g.c.g.agccacccagtccgtcttactaagcatacctaatatacctctcgtatgcaccagcaccagatcgcttctcacatcaa.g..aggccgaccgttactacctgccaatcgttcgaggacgccgaagccacatgggtcacgagtccatgcagcaccgacccctgactctagtcgatagtttgagctaggtgcacgacgctagcgaatgggcactcctagctaacgatgccgctcgcgattcgatagttactttgtagcctgaactggagggcgagggaagcctggtcatcgtctcctca Server 1_Summary 38 M67502 productive IGHV1-46*01, or IGHV1-I4G6H*0J24 *o0r2 IGHV1-46*03IGHD3-10*01 caggtgcagctgctgcagtctggggctgaggtgaggacaaggcgcttggcgagggcctcgtcctagcgcatagggagtactgtagcagatgtgtcgcctgttgccatgagcagagtgcatctctgactgtcgatcgatgtccatctgtcgatacgtccgtcttgcttgcacacgtttcacggatgacgacttgtgacacccagttaagttacgcttagatcgtgacagccccttgctcgcctgaacggcattgggcagaagcatcgacacagtcactagcatgtactgctccagatcgtcctctactgacgcacagagtggattcgaatcgcttaacgtgatcggactgggctgtgcaacgacgtcgttagagtaggtttgatgcttggatgtccgatgtggtcgcgcgcagacgttgattcgacgctaaactgatcagtttatgcgagacgggtaggccatgccggacgaacgtcacgcgcttgcgcagactcgcacgtactgtagcgagcactgtcagcgattgacgtctgatcgcaacttgagggaagagtgttgtatacacgtcaagagcgcctagtgaaaggtagtctgcgtgccgtaacgtagacacacaacccagcggtgacgctacctaaactcagtgttacacatagctttgcacgacgggcgacgatgatagctactggcgcaagtgttagcacgacgaggccatcgaacggattccctgatcaggaagccagccgaggctcgatatactaattgtagcatgttggcatggcagcttctaggagggagtcgttgtgacgcaccgagccgcgttctacgagtagtgaattactcgtgtgggcctgcaggaggatccctggtcaccgtctcctca resources 34 Z80499 productive IGHV3-23*01, or IGHV3I-G23H*J034*02 IGHD3-3*01 ...... ttggtacagcctgggg.g..g..t.c..c.c..t.g..a..g..a..c..t.c..t.c..c...t..g....t..gt.t.cg..ag..gt.a.c.c.c.at.c.g.t.cg..cg..ta.g.t.gt.c.g.a.ga.ctgttgcttagttc.ct.ca.t.ct.t.tta.g...g.a...c.g..c.a.t.gc..ctga.c.agtatggcgacgcatagcgtttcggccctgcacgttaggttcacgcgcagtaccactcgtttacgatgagcgtgctgcctcgtacctcgcgtagctctgatct..g.a...gc..a..ca.g.ag.tac.cg.tgt.tct.agt.cacgatggagccgatcggaagcacatcaggtctcgtggcgcgagcgtcagtatctaggtagcagaag.gc..ttcgtgtgtgccgtggtctgtctcggtcgcggcagctgagcctgactaaacggtcgtgaatctgtgctctctcgttcctgtacttgtttgactagttgagt.gtag.ac.ga.t.gcg.ggtaggcaggtgtgttgagcgttctatgccggatctagtatgagctagctagaaagtcctcgtgatccgctaggtcatatacgtagtacgtactagcagttgagat.cg..a..g.gtcgtctgtcagtgagagcgctcaaccgcacaaagatgcatcaccaagcgcgaggcaccgatcaacttatgctttcgacacaatggta..a.gcgaccggcgtacttactacctgccaatcatactcgaagaacgaagctcatagtatcgcacgacgcagacgagcagccatcagtagtccctgctaataatttagcatgatcgacggtacgtgaaggaaggccccttgcatgggggagcgaccggtctctgttttagtaattatatccttgggtggcggcagaga providing links to IMGT/2Dstructure-DB and IMGT/3Dstructure-DB for entries 2 Resource 2 Sequence number Sequence ID Functionality V-GENE and allele V-REGION score V-REGION identity % V-REGION identity nt V-REGION identity % (with ins/del events) V-REGION identity nt (with ins/del events) J-GENE and allele J-REGION score • Results of IMGT/JunctionAnalysis 31 L32565A3F1013615 produuncktinvoew (nsee comIGmHenVt6)-1*IG01HV5-51*01 1201 90.97 262/288 nt 90.62 caggtacagctgcagcagtgctaagcgatgccctag.c..aggggcaagcgtgtgcgaatcgaagg2atct6ggc1ctac/.2tc.c.8tgtc8.g. .ta.ngc.ca.gtatgaggagcctagctagcacgtacagtgtccctacgaccgtttcaggagcccatcatgatgtgcattcgacccccccaaatgcttcgctcgtcagccagg.tta.cgt.aggtgacgcgactctgcatatgggttacatIcgGttcgatcgHtcatgctgatcJttcgat4.tacg.*g.0ga.g.a.2gga.aag..acagagtccgaagatgtacatgccctatgtcgaacctgcgaagtaccaag1cga7cta2cgctacaccgcaaatcccgaaggtatcgtgccctttggcaaggtgcgttcgtagtgtcgtagatggagcatcactcagcatagcgaagcgatccgcg..c.atgatggttgagtttactatgattgattatgcagtatctgtgaga...agtcgaataaccatcaacccagacacatccaagaaccagttctccctgcagcttgattctgtgactcccgaggacacggctgtgtattactgtgcaagaga 32 L32619A5F7013616 prodpurcotdivuec t(isvee comIGmHenVt4)-31IG*0H3V, 6o-r1 IG*0H1V4I-G31H*J034*02 14IG44HD983.-635*01 cgggtg2c9c3g/c2t9g7c angtgagtcgggccca.9..8g.g3a2ctcggggtgatgacgccgcccttgccaacgagcgagagctgccctggtgctgcccgccccttgcaca..ac.gcgtggagccgtagttgcagtcgtgtgtccgac2tccat9tctgcg2ccaga/c2gt.gc.c9.tag.7c.cg. ta.ngta.c.tgcaatgtgtgctagcactgtgcgtacg.tagc.g.gt.ttc.ca.ccacgcgtctatcgctacgacgtggcacgtgttgttcatcaccaccacatcgtgcttgt.gg.ct.gcgt.gc.aa.atc.ag.ct.ggctgatagggccggaacgccatgttcgccgacgtIactGgcgctgtcagHctagtgcJgcact3c.atg.*ct.t0ca.ta.gc1t.acacg,gc gago.ctgc.grc.g agtIgcGtgatHtcgtatgtJgttga3agcc*ggt0tgctta2cggcttggcaggattcatgacgactttgcattgtgtcgaactttgtggtccgagcatgagtctcactaggac1gatac9agtagta1cgtctacttctatgtctagagactaggctattagatagccgacttcgctttag..ata.t.gact.a.gt.ct.gtc.cagcaccgcgtagtagtgagagaatgctgagctctgcgctgtagtatcagtctcaggtttcgatatcgccttcatcgtacgactgcaatctgcgcgtcacgttccatgcgaagctg.a..c..ag..gg..tcgcggagtcggtgtaccactcaacctggtgaatcctgaactatgaaccaccgctctctcatacgaaagc..c.atggtttccgtcacccttagcacaagtcgtagcggcactctgtcatcgaaccctgtcctcagacggagaaccatgctgtcgtccgctgtaaacgtacctgtggtcgcctgcatcgtgaatccctcgcctccgacttggggaccgagcggggttcacttgattggtcagcataacatgtagcagtaggaatgcttttgatatctggggccaagggagaatggtcaccgtctcctcag available in these databases, IMGT/mAb-DB facilitates comparative studies of In November 2010, IMGT/mAb-DB contains: 17 INN radiolabelled and Local Analysis Queue Dispatch of each selected [14] Lefranc, M.-P. et al., Nucleic Acids Res. 37: 1006-1012 (2009) analysis to the proper 33 X39740A7F5013619 prodpurcotdivuec t(isvee comIGmHenVt4)-39IG*0H1V5-a*03 IGHJ4*02 13IG09HD956.-1143*01 cagctg2c7a4g/c2t8g8a angtgagtcgggccca.9..4a.g7a9ctcgaggtcgtagacgaggcctttgcagaggagcagcctcctgtgctagcgcccccttgcaa..ac.agcgtgagcctgagttgcctgcgttgcgcgca2ctac7cgt3cgg/ag2c.gt8.tg.ta8c.g.g .tcn.gga.t.tgcacagtggaatgtaccttgcagtcgattag..gt.ct.ga.c.cagcttgtcactctgacagctgacatacttgtgcaactttcgacacgcccattg.tag.c.cg.tc.tg.ttc.aca.gc.ctagttcgagagctgctaggcgaggtccggtctggtcacgIgcaGagttcgHcccatgcJgcga4gtttcg*.a.a0ct.t.cat2.g.cgaagc.tg.gc.tagagcgatgtctagggtatattgtatgtacgtgcgctacgagacgccagctgactgtaaggtctgagcgtcttgcttgggatgatgcacgtttttatcttgacgtcgtatcgag1ccgtag6tacgtgtt3gacgtgccaactaccccattcagcttagtcagatcatgccagtatctgt.gca.a.tct.taa.c.gtt.gtc.gt.gtcggtcgcatgacgcatcatgcgggtgcgtagttcgtgcgttcgatcgatactatacgtcgagtagacagctcggtctcctcacgtctcatcatagagagtc..a..ca..gg..gt.cggtgagtgattgcttcatagccctcagttatactctaccgataagcacccagctcgctcgtcaaaagga.a..cacgatcggttacgtctccatcgcaagtgattcgcagatacgtcatgctagcagctcgcacaggcaaagcaccaagcttgcgtccctgcttgtattgtagctttgatgaccgtcatggatgcactgcggccacggtcttatggcaccaagccgagcccttggtgtctttttatacttagtttgttcggaacgtcatctgagggccagggaaccccggtcaccgtctcctcag computational resource Resource N 34 Z38804M9697502 prodpurcotdivuec t(isvee comIGmHenVt1)-46IG*0H1V, 3o-r2 IG3*H0V1,1 Io-G4r 6HIG*J04H2* V0o23r -I2G3H*0V41-46*0131IG86HD953.-7140*01 caggtg2c4a7g/c2t5g8c tngtcagtctggggct...g9a5g.3g5tgcaaggggataggccacgtcgtgggcgtgccccatacgagtcgttgggacgagacattt.gt.t.cgtcagtgcgagcggatgctatcatgtcggctgcgacaga2ttgtcg4cctc.6gt..c.g/..2.t.cg.5t.agt.8c.g. tt.ntgc.tatcgtactctatcacgt.cag..cg.a.tt.gag..tgca.g.tca.ca.cagttatgctcgaatatgccgcagctagccctctacaaccattgtcgattgtcgcgcta.a.ac.cta.atc.gac.atgctgtttatcggcctggcttcgctac.at.cgac.ataItgcGcggat.cgg.Hca.cg.tgJa.cga.t3tc.gttc.c*g.at.0cg.g.2aggatgtatcc.aga.a.ctgcagcggctgataggcgtgtgatcgctgttgtttgtccgagcaagccgtcgtatggttcggaacgattgatcgtgccagtagaggaggcgtgagagccgtccac8acg3agcgcctgcccacgcatgcatctacgtgacta.gta.g.g.gc.g.gtgccgagatcggctgtggcgta.ca.g.tcactagcctagtgcagactagcgtatgtcgatagcgtaaccaatggccacatcgctatccgtcaatgcgtt..g...t.ga..ggcagactgagacgc.tg.c.cgaccacatatctgacatttacccattcggatgcgaagcaaacggtttccccaacgg..a.ggccgacgaagtggttcagccactagtggaagctctgaagggcgaagccacctgatcgcaatctggataggcgacacggtggtcacattagtgaattgatctgtgatgcatgggcacgtgttacgaagtgcgtgtgatgagcaccggcctattagtagtgtagcatgctggctggggcacgagggatccctggtcaccgtctcctca antibodies and FPIA, and of their constitutive chains, even if 3D structures are 11 INN conjugated. [15] Giudicelli, V. and Lefranc, M.-P., Bioinformatics 15: 1047-1054 (1999) Transfer of the results to the 35 AF013615 unknown (see comment) IGHV6-1*01 1444 98.65 293/297 nt 98.32 292/297 nt [9] World Health Organization. INN Working Document 09.251.Update 18/12/2009 local server and notification of Preparation of the results 36 AF013616 productive (see comment) IGHV4-31*03, or IGHV4-31*04 1234 91.75 267/291 nt 91.41 266/291 nt IGHJ3*02 232 [12] Brochet et al. Nucl. Acids Res. 36: W503-508 (2008) of completed analyses [10] Jefferis R, Lefranc M-P. mAbs 1:332-338 (2009) [16] Duroux, P. et al., Biochimie 90: 570-583 (2008) concerned user by e-mail 37 AF013619 productive (see comment) IGHV4-39*01 1315 94.85 276/291 nt 94.5 275/291 nt IGHJ4*02 186 not yet available. [13] Yousfi Monod et al. Bioinformatics 20: i379-i385 (2004) 38 M67502 productive (see comment) IGHV1-46*01, or IGHV1-46*02 or IG1H1V861-4960*.8083 259/285 nt 90.53 258/285 nt IGHJ4*02 145 [11] Lefranc M-P. mAbs 3:1-2 (2011)